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CHAPTER-I 
INTRODUCTION 
 Nanotechnology is derived from the Latin word “nano”, which means 
dwarf. One nanometer (nm) is equal to one-billionth of a meter, or about the width of 
6 carbon atoms or 10 water molecules. A human hair is approximately 80,000 nm 
wide, and a red blood cell is approximately 7000 nm wide. Atoms are smaller than 1 
nm, whereas many molecules including some proteins range between 1 nm and larger. 
The conceptual underpinnings of nanotechnologies were first laid out in 1959 
by the physicist Richard Feynman in his lecture, There’s plenty of room at the bottom. 
Feynman explored the possibility of manipulating material at the scale of individual 
atoms and molecules, imagining the whole of the Encyclopedia Britannica written on 
the head of a pin and foreseeing the increasing ability to examine and control matter 
at the nanoscale. The term nanotechnology was not used until 1974, when Norio 
Taniguchi, a researcher at the University of Tokyo, used it to refer to the ability to 
engineer materials precisely at the nanometer level. The primary driving force for 
miniaturization at that time came from the electronics industry, which aimed to 
develop tools to create smaller (and therefore faster and more complex) electronic 
devices on silicon chips. 
In medicine and pharmaceutics, nanotechnology is used to improve human 
health at a molecular level. The novel and potential applications of nanotechnology in 
pharmaceutics are; development of diagnostic tools, formulation of drug carrier 
systems and gene therapy. The advantages of nanotech drugs compared to 
conventional counterparts lie on the basis of particle size. Drugs/drug products with 
nano dimension can be used at a lower concentration and can lead to early onset of 
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bioactivity. Nano drug delivery systems (nanopharmaceutics) are, but not limited to, 
nanocapsules, nanospheres, nanosponges, nanoemulsions, solid lipid nanoparticles, 
nanovesicular systems (liposomes, niosomes), molecular systems (inclusion 
complexes) and nanocrystals. 
Absorption of a drug is defined as the transition of a drug from the applied 
place to the blood and/or lymphatic circulation. The amount of absorbed active drug 
substance depends on physicochemical properties of the active drug substance, 
pharmaceutical dosage form and physiological characteristics. For complete 
absorption of the active drug substance from the gastrointestinal tract (GI), it must be 
completely dissolved (Figure 1). However, most of the new chemical compounds 
developed as a drug have poor solubility in water. Water solubility of 40% of the 
active drug substances that are currently in use and 60% of the active drug substances 
that are at the investigation stage is very low. Low water solubility limits absorption 
and bioavailability of these drugs. For oral administration, conventional formulations 
of poorly water-soluble drugs are associated with erratic absorption in the GI tract and 
low/variable bioavailability. 
 
 
 
        Dissolution                            Absorption 
FIGURE 1: SCHEMATIC REPRESENTATION OF EVENTS THAT AN 
ACTIVE DRUG SUBSTANCE FACES IN THE GI MEDIUM 
(Tugba Gulsun et al., 2010) 
Thus, bioavailability of poorly water-soluble drugs will be affected positively 
when their dissolution rate is increased. These drugs show serious adverse clinical 
effects like non-steady absorption due to variability among patients and individual 
Solid active drug 
substances in 
gastrointestinal 
medium                           
Soluble active 
drug substances in 
gastrointestinal 
medium 
Active drug 
substances in 
systemic circulation 
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patient dosing. Drugs which have high permeability but low solubility (Class II 
according to Biopharmaceutics Classification System) are not easily dissolved so they 
may not be absorbed from the GI tract sufficiently. Moreover, such drugs 
incorporated into conventional dosage forms are usually affected by the fasted or fed 
state of the patient. This situation eventually causes inappropriate dosing and low 
bioavailability. 
Pharmaceutical approaches 
For improving solubility of drugs, in order to enhance oral bioavailability. 
Solubilization of poorly water-soluble drugs increases dissolution rate and absorption 
leading to a significant improvement of drug bioavailability. Approaches to improve 
the solubility or to increase the available surface area for dissolution are classified as 
physical and chemical modifications.  
 Physical modifications are decreasing particle size (micronization, 
nanosuspensions), formation of polymorphs/pseudopolymorphs (including 
solvates), complexation/solubilization (use of surfactants or cyclodextrines, 
addition of cosolvents) and preparation of drug dispersions in carriers (eutectic 
mixtures, non-molecular solid dispersions, solid solutions).  
 Chemical modifications are synthesis of soluble prodrugs and salts.  
Approaches such as adding a surfactant/cosolvent, complexation with 
cyclodextrins or/and preparing oil–in-water emulsions for intravenous applications 
have been developed for poorly water-soluble drugs, but these approaches have 
limited application since the active drug substance must have specific 
physicochemical properties (for example, cyclodextrins must have suitable molecular 
weight for optimal conjugation of the conical structure with the drug for such 
applications to be successful).  
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Solid dispersions are theoretically one of the appropriate methods for 
increasing dissolution rate, but molecules in the amorphous state are not 
thermodynamically stable; they can convert to the crystal form during storage. The 
use of surfactants or cosolvents sometimes leads to increased side effects and toxic 
reactions in the body. Potential disadvantages of salt forms include, high reactivity 
with atmospheric carbon dioxide and water resulting in precipitation of the poorly 
water-soluble drug. Polymorphs are different crystalline forms of a drug that may 
have different physicochemical properties and biological activities with respect to 
morphology, density, melting point, hardness, compression, solubility and 
bioavaliability. Therefore, the preparation of actual drug polymorphs is crucial during 
preformulation studies. An alternative drug delivery approach called micronization, 
has been developed to overcome poor solubility in water. Micronization of poorly 
soluble drugs, increases the dissolution rate of the drug due to the increase in surface 
area, but does not change the saturation solubility. In order to increase solubility and 
oral bioavailability, going down to the micron level may sometimes not be sufficient, 
so the next step, going down to the nano level, may be necessary. 
Dissolution Rate vs. Particle Size   
Intrinsic solubility can be explained as the number of moles of a substance per 
liter which dissolves in a particular solvent. Thus, dissolution is the process by which 
a solid substance dissolves. There are many factors that effect solubility; such as pH, 
cosolvent, surfactants, temperature and particle size. By changing these factors, 
solubility of active drug substances can be modified. Dissolution rate has been first 
described by Noyes and Whitney in 1897. In 1904, Nernst and Brunner explored the 
dissolution rate constant and diffusion coefficient of solutes. According to the Nernst 
Brunner equation, dissolution rate is proportional to the surface area of the active drug 
substance in contact with the dissolution medium. 
CHAPTER-I                                                                                       INTRODUCTION 
 
Ramipril Nanocrystals Reg No: 261211301 Page 5 
 
 
Dw/dt =  D/h × S (Cs – Ct) 
Where, 
dw/dt: Dissolution rate (mg/s) 
S: Effective surface area of the solid drug (cm2) 
Cs-Ct: Concentration gradient (mg/mL) 
Cs: Saturated concentration(mg/mL) 
Ct: Concentration of the solute at time t (mg/mL) 
 h:   Effective diffusion layer thickness (cm) 
D: Diffusion coefficient (cm/s) 
It can be deduced from the formula that changing particle size of the active 
drug substance, it is possible to change the specific surface area and the dissolution 
rate of the active drug substance in body fluids (Figure 2). With this basic 
information in hand, it is clear that the dissolution rate and bioavailability of poorly 
water soluble drugs can be increased by decreasing the particle size of active drug 
substances. Additionally, particle size reduction results in a decrease in the diffusion 
layer thickness surrounding the drug particles and an increased concentration gradient 
between the surface of the drug particles(Tugba gulsun et al., 2009). 
Total surface area 6cm
2
    Total surface area 12cm
2
      Total surface area 24cm
2
 
FIGURE 2: SURFACE AREA ENLARGEMENT BY PARTICLE SIZE 
REDUCTION NANONIZATION STRATEGIES FOR POORLY WATER 
SOLUBLE DRUGS (Huabing Chen et al., 2011) 
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Nanonization of hydrophobic drugs generally involves the production of drug 
nanocrystals through either chemical precipitation or disintegration. Alternatively, 
nanotechnology-based drug delivery systems such as nanoemulsions and polymeric 
micelles can be used. During the past decade, several drug nanoformulations have 
been clinically approved or are under clinical investigation. Major research efforts 
have been focused on the development of enabling nanoformulation technologies, 
new pharmaceutical materials and quality control to improve product properties while 
reducing production costs. New technological advances and unmet clinical needs 
provide the key driving force for the research and development of nanonization 
strategies. 
a) Drug nanocrystals 
Drug nanocrystals are nanoscopic crystals of the parent compound with 
dimensions less than 1 mm. According to the Noyes–Whitney equation , a decrease in 
particle size will lead to an increase in effective surface area in the diffusion layer, 
which, in turn, increases the drug dissolution rate. Drug nanocrystals are one of the 
most important strategies to enhance the oral bioavailability of hydrophobic drugs. 
Several following preparation methods for drug nanocrystals have been investigated 
they are, 
 Nanoprecipitation, 
 High-pressure homogenization and 
 Media milling. 
b) Nanoemulsions 
Nanoemulsions are a nonequilibrium, heterogeneous system consisting of two 
immiscible liquids in which one liquid is dispersed as droplets in another liquid. 
Emulsions with nanoscopic droplet sizes (typically in the range of 20–200 nm) are 
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often referred to as submicron emulsions. Nanoemulsions are composed of oil 
droplets dispersed in an aqueous medium and stabilized by surfactant molecules 
(Figure 3). Although nanoemulsions have a tendency for phase separation, kinetically 
stable nanoemulsions can be achieved with sufficient shelf stability and no apparent 
flocculation or coalescence. Advantages of nanoemulsions include increased drug 
loading and enhanced bioavailability. Commercial products that are nanoemulsions 
include Estrasorb1 and Flexogan1. 
 
In a nanoemulsion, the oil droplets serve as the reservoir for hydrophobic 
drugs. The most widely used oil molecules include saturated and unsaturated fatty 
acids, fatty acid esters and soybean oils. Surfactant molecules play a key part in 
stabilizing the nanoemulsions. Nonionic or amphoteric surfactants such as poloxamer, 
lecithin and Tween 80 are commonly used. Combinations of various surfactants have 
also been used to control droplet size and improve the stability of nanoemulsions. The 
methods used for the production of nanoemulsions include  
 
 High pressure homogenization, 
 Microfluidization, 
 Ultrasonication and 
 Spontaneous emulsification. 
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FIGURE 3: SCHEMATIC OF DIFFERENT NANONIZATION STRATEGIES 
TO INCREASE DRUG SOLUBILITY AND BIOAVAILABILITY 
c) Polymeric micelles  
 
Polymeric micelles have received considerable attention in the past two 
decades as a new multifunctional nanoplatform for the delivery of hydrophobic drugs. 
Polymeric micelles are nanosized (typically in the range of 20–100 nm) 
supramolecular constructs (Figure 3) formed from the self-assembly of amphiphilic 
block copolymers in aqueous environments. In water, the hydrophobic segment of the 
block copolymer self associates into a semisolid core, with the hydrophilic segment of 
the copolymer forming a coronal layer. The resulting core–shell architecture is 
important for drug delivery purposes; the hydrophobic core serves as a reservoir for 
water-insoluble drugs, and the outer shell protects the micelle from rapid clearance in 
circulation. 
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Poly(ethylene glycol) (PEG) is most commonly used for the hydrophilic 
segment. PEG molecules are biologically inert. Moreover, they are shown to prevent 
nonspecific protein adsorption to the micelle surface prolonging the blood circulation 
time of the micelles. Other polymers, such as poly(N-vinyl pyrrolidone) and poly(N-
isopropyl acrylamide), are also used as hydrophilic blocks but with much less 
frequency. Compared with the hydrophilic blocks, the chemistry of core-forming 
hydrophobic polymers is much more diverse. Polyesters and poly(L-amino acids) are 
the most widely used polymers because of their biocompatibility and 
biodegradability. Examples include, but are not limited to, poly(lactic acid) (both L-
isomer, or PLA and D,L-isomer, or PDLLA);  poly(e caprolactone); poly(L-aspartic 
acid) (pAsp); and poly(L-glutamic acid). Recently, a new hydrotropic polymer design 
was reported to form polymeric micelles with high drug loading and excellent 
physical stability. This process involves the screening of hundreds of 
pharmaceutically safe molecules to identify candidate structures that enable 
heightened solubility for a chosen drug; then, the structural motif is incorporated as 
the hydrophobic segment to enhance its interactions with the drug. Using this 
approach, Park and co-workers have developed hydrotropic copolymers consisting of 
PEG and poly(4-(2-vinylbenzyloxy-N-picolylnicotinamide)) that provide efficient 
encapsulation of paclitaxel with high loading . This method might provide a universal 
strategy to produce tailor-made polymeric micelles that can achieve high drug loading 
and stable encapsulation of a wide variety of drugs. The methods used for the 
production of polymeric micelles include 
 Dialysis,  
 Solvent evaporation and   
 Film sonication. 
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COMPARISON OF DIFFERENT NANOFORMULATION STRATEGIES 
Currently, the formation of drug nanocrystals is the most established technique 
among the three strategies discussed in this review, with multiple clinically approved 
products. Large-scale production of drug nanocrystals is feasible with excellent 
reproducibility. This technique can formulate drugs with a wide range of solubility 
profiles, including drugs that are not soluble in either water or oils. The precipitation 
methods can also formulate drugs into amorphous or semicrystalline nanoparticles, 
whereas homogenization and media milling methods work better with drugs that have 
a high degree of crystallinity. 
Drug nanocrystals also have fast dissolution rates, which make them an 
excellent choice for oral delivery. However, this strategy sometimes requires high-
energy input, resulting in high production costs. Moreover, formulated nanocrystals 
often require surface stabilization. Owing to the fast dissolution kinetics nanocrystal 
formulations are not suitable for cytotoxic drugs with small therapeutic indices such 
as anticancer agents. 
Nanoemulsions offer some crucial benefits over other nanonization 
techniques. High drug-loading content can be achieved easily using many clinically 
approved pharmaceutical ingredients (e.g. small molecular surfactants, lipids and 
oils). The production process is also inexpensive. Nanoemulsions are used for topical 
administration with several clinically approved products. Other routes of 
administration for drugs with large therapeutic indices are also used clinically. Drug 
nanoemulsions often suffer from poor stability, with the possibility of flocculation and 
coalescences upon storage. The lack of a controlled release mechanism is also a 
limitation for this nanoformulation technique to deliver cytotoxic agents. 
Polymeric micelles have been explored extensively in the past decade because 
they can achieve improved blood stability and have excellent controlled release 
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properties. The higher hemostability of micelles allows prolonged circulation, 
enabling passive and active targeting to tumors for cancer treatment. In addition, a 
multifunctional design for polymeric micelles can also be achieved by incorporating 
imaging agents and therapeutic agents in the same micelle. Polymeric micelles are 
also suitable for intravenous administration to deliver a variety of cytotoxic drugs, a 
potential advantage over nanocrystals and nanoemulsions in cancer chemotherapy. 
The disadvantages of micelles include concerns over the safety of polymer carriers; 
only a few polymers, such as PLA, are clinically approved. 
 
CHAPTER II 
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CHAPTER-II 
NANOCRYSTAL TECHNOLOGY – A REVIEW 
Preparation of drug nanocrystals is basically a nanosizing method, which is 
utilized to enhance the oral bioavailability of poorly water-soluble drugs. Drug 
nanocrystals are nanoscopic crystals of the drug with dimensions less than 2000 nm as 
defined in the first patents in this field. Nanocrystal dispersions contain dispersion 
media (water, aqueous solutions or nonaqueous media), active drug substances and 
surface active agents or polymers required for stabilization. If necessary, other 
substances such as buffers, salts and sugars can be added. 
There are many advantages of nanocrystal formulations designed for oral 
administration. They are as follows: 
• Increased rate of absorption, 
• Increased oral bioavailability, 
• Rapid effect, 
• Improved dose proportionality, 
• Reduction in required dose, 
• Applicability to all routes of administration in any dosage form. Contrary to 
micronized drugs, nanocrystals can be administered via several routes. Oral 
administration is possible in the form of tablets, capsules, sachets or powder; 
preferably in the form of a tablet. Nanosuspensions can also be administered via the 
intravenous route due to very small particle size, and in this way, bioavailability can 
reach 100 %, 
• Reduction in fed/fasted variability, 
• Rapid, simple and cheap formulation development. 
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• Possibility of high amounts (30-40 %) of drug loading, 
• Increased reliability. Usually side effects are proportional to drug 
concentration, so decreasing the concentration of active drug substances leads to an 
increased reliability for patients. 
• Sustained crystal structure. Nanocrystal technology leads to an increase in 
dissolution rate depending on the increase in surface area obtained by reduction of the 
particle size of the active drug substance down to the nano size range preserving the 
crystal morphology of the drug. 
• Improved stability. They are stable systems because of the use of a stabilizer 
that prevents reaggregation of active drug substances during preparation. Suspension 
of drug nanocrystals in liquid can be stabilized by adding surface active substances or 
polymers, 
• Applicability to all poorly soluble drugs because all these drugs could be 
directly disintegrated into nanometer-sized particles(Tugba Gulsun et al., 2010). 
PROPERTIES OF NANOCRYSTALS  
The main reasons for the increased dissolution velocity and thus increased 
bioavailability are: 
Increase of dissolution velocity by surface area enlargement 
The size reduction leads to an increased surface area and thus according to the 
Noyes-Whitney equation to an increased dissolution velocity. Therefore 
micronization is a suitable way to successfully enhance the bioavailability of drugs 
where the dissolution velocity is the rate limiting step. By moving from micronization 
further down to nanonization, the particle surface is further increased and thus the 
dissolution velocity increases too. In most cases, a low dissolution velocity is 
correlated with low saturation solubility (Figure 4). 
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FIGURE 4: SURFACE ENLARGEMENT AND INCREASE IN NUMBER OF 
CRYSTALS BY PARTICLE SIZE DIMINUTION 
(Rainer H Muller et al., 2008) 
Increase in saturation solubility 
The general textbook statement is that the saturation solubility Cs is a constant 
depending on the compound, the dissolution medium and the temperature. This is 
valid for powders of daily life with a size in the micrometer range or above. However, 
below a critical size of 1–2 μm, the saturation solubility is also a function of the 
particle size. It increases with decreasing particle size below 1000 nm. 
Therefore, drug nanocrystals possess increased saturation solubility. This has 
two advantages: 
1. According to Noyes and Whitney (1897), the dissolution velocity is further 
enhanced because dc/dt is proportional to the concentration gradient (Cs-Cx)/h 
(Cs- saturation solubility, Cx - bulk concentration, h - diffusional distance). 
2. Due to the increased saturation solubility the concentration gradient between 
gut lumen and blood is increased, consequently the absorption by passive 
diffusion (Figure 5). 
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 FIGURE 5:COMPARISON OF A MICROCRYSTAL (A) AND A 
NANOCRYSTAL (B) AND THEIR SURFACE CURVATURE AND 
CONCENTRATION GRADIENT OVER THE DIFFUSIONAL DISTANCE (h). 
Abbreviations: Cs, drug-saturated water at surface (M, microcrystal; N, 
nanocrystal); Cx , bulk concentration at diffusional distance; h, diffusional distance. 
dc / dt ~ (Cs – Cx) /h (Rainer Muller. H et al., 2008). 
Advantages of an amorphous particle state: 
It is well known that amorphous drugs possess a higher saturation solubility 
compared to crystalline drug material. Amorphous drug nanoparticles possess a 
higher saturation solubility compared to equally sized drug nanocrystals in the 
crystalline state. Therefore, to reach the highest saturation solubility increase, a 
combination of nanometer size and amorphous state is ideal. 
Transferring all these facts to drug nanocrystals means that optimal drug 
nanoparticles with the highest increase in saturation solubility should have a size of 
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eg, 50 nm or 20–30 nm, and be amorphous. It can be concluded that the size matters 
regarding the increase in saturation solubility and consequently the increase in 
dissolution velocity caused by a higher Cs combine drug nanocrystals with traditional 
controlled release technology (eg, coated pellets) to avoid fast dissolution, excessively 
high plasma peaks and premature tmax and to reach prolonged blood levels.  
To summarize, the optimal drug nanocrystal size and crystalline/amorphous 
state will depend on: 
1. Required blood profile. 
2. Administration route. 
3. Stability of the amorphous state during shelf life of the product (Rainer  
Muller. H et al., 2008). 
NANOCRYSTAL PREPARATION METHOD 
Several preparation methods for drug nanocrystals have been investigated. 
1. Bottom-up technology 
 Nanoprecipitation 
2. Top-down technology 
 Homogenization  
 Ultrasonic homogenization. 
 High pressure homogenization. 
 Milling 
3. Top down and Bottom up technology 
Today, implemented preparation methods of nanocrystal formulations 
can be classified as “bottom- up”, “top-down”, “top down and bottom up”. 
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 “Bottom up” technology begins with the molecule; active drug substance is 
dissolved by adding an organic solvent, and then, solvent is removed by 
precipitation.  
 “Top-down” technology applies dispersing methods by using different types 
of milling and homogenization techniques. “Topdown” technology is more 
popular than “Bottom up” technology; it is known as “nanosizing”. In other 
words, it is a process which breaks down large crystalline particles into small 
pieces. 
 In “top down and bottom up” technology, both methods are utilized together. 
Spray drying is also a method for preparing drug nanocrystals, which is faster 
and more practical compared to the other methods (Tugba Gulsun et al., 
2010). 
1. Bottom up technology 
 Nanoprecipitation 
The nanoprecipitation method involves the formation of crystalline or 
semicrystalline drug nanoparticles by nucleation and the growth of drug crystals.  
In a typical procedure, drug molecules are first dissolved in an appropriate 
organic solvent such as acetone, tetrahydrofuran or N-methyl-2-pyrrolidone at a 
supersaturation concentration to allow for the nucleation of drug seeds. Drug 
nanocrystals are then formed by adding the organic mixture to an antisolvent in 
the presence of stabilizers such as hydroxypropyl methylcellulose, 
polyvinylpyrrolidone, Tween 80, Poloxamer 188 or lecithin. The choice of 
solvents and stabilizers and the mixing process are key factors to control the size 
and stability of the drug nanocrystals. A combination of several stabilizers is often 
used for optimal effect. 
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The primary role of stabilizers is to inhibit excessive crystal growth or particle 
aggregation. The mixing step is crucial to produce a rapid and uniform supersaturated 
solution, which facilitates the formation of uniform and small drug nanoparticles. 
Other crucial factors include the drug concentration, volume ratio of antisolvent to 
solvent, temperature and viscosity (Huabing Chen et al., 2011). 
Examples of products manufactured by the precipitation method are, 
Hydrosols and Nanomorph TM, which are developed by Sucker and Soliqs/Abbott 
respectively (Tugba Gulsun et al., 2010). 
2. Top down technology  
“Top down” technology can be applied by either homogenization or milling. 
 Homogenization 
i)Ultrasonic homogenization 
ii)High pressure homogenization 
i) Ultrasonic homogenization 
One of the preparation methods of nanocrystals is homogenization by 
ultasonification. Ultrasonic probes are used to decrease the particle size in liquid or 
solid dispersed phase. Ultrasonic homogenization is quite effective for reducing the 
size of hard and soft particles. Homogenization by ultasonification is based on high 
frequency mechanical vibrations. Liquids are exposed to intense sound waves 
transmitted with ultrasonification. Ultrasonic probe provides controlled and 
reproducible ultrasonification. This is important for the quality of manufactured 
products and scale up studies (Tugba Gulsun et al., 2010). 
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ii) High-pressure homogenization 
Another homogenization method is high pressure homogenization in which 
two types of homogenizers namely, microfluidizers and piston gap homogenizers 
are used. 
a) Microfluidizer Technology  
The microfluidizer is a jet stream homogenizer of two fluid streams collied 
frontally with high velocity (up to 1000m/sec) under pressures up to 4000 bar. There 
is a turbulent flow, high shear forces, particles collied leading to particle diminution 
to the nanometer range. The high pressure applied and the high streaming velocity of 
the lipid can also lead to cavitation additionally, contributing to size diminution. To 
preserve the particle size, stabilization with phospholipids or other surfactants and 
stabilizers is required. A major disadvantage of this process is the required production 
time. In many cases, 50 to 100 time- consuming passes are necessary for a sufficient 
particle size reduction. Skye Pharma Canada, Inc. (previously RTP, Inc.) applies this 
principle for its IDD-P™ technology to produce submicron particles of poorly soluble 
drugs. 
b) Piston-gap homogenization in water (Dissocubes®) 
Drug nanocrystals can also be produced by high-pressure  homogenization 
using piston gap homogenizers. Depending on the homogenization temperature and 
the dispersion media, there is a difference between the Dissocubes® technology and 
the Nanopure® technology. Dispersion medium of the suspensions was water. A 
piston in a large bore cylinder creates pressure up to 2000 bar. The suspension is 
pressed through a very narrow ring gap. The gap width is typically in the range of 3-
15 micrometer at pressures between 1500-150 bar. There is a high streaming velocity 
in the gap according to the Bernouli equation. Due to the reduction in diameter from 
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the large bore cylinder (e.g. 3 cm) to the homogenization gap, the dynamic pressure 
(streaming velocity) increases and simultaneously decreases the static pressure on the 
liquid. The liquid starts boiling, and gas bubbles occur which subsequently implode, 
when the suspension leaves the gap and is again under normal pressure (cavitation). 
Gas bubble formation and implosion lead to shock waves which cause particle 
diminution. The patent describes cavitation as the reason for the achieved size 
diminution (Suman Katteboinaa et al., 2009). 
Nanopure® Technology 
Another approach using the piston-gap homogenizer is the Nanopure® 
technology, owned and developed by Pharma- Sol GmbH in Berlin. The technology 
uses dispersion media with a low vapor pressure and optionally homogenization at 
low temperatures. The cavitation in the homogenization gap is very little or 
nonexistent. Even without cavitation, the size diminution was sufficient. The 
remaining shear forces, particle collisions and turbulences are sufficient to achieve 
nanoparticles. The optional low temperatures while homogenizing allow the 
processing of temperature labile drugs. It is possible to carry out the whole process in 
non-aqueous media to protect drugs from hydrolysis. Usage of oils, PEG or hot-
melted polyethylene glycols can be directly filled into gelatin or HPMC capsules 
(Rainer Muller. H et al., 2008). 
 Milling  
  In the milling method; pearl, bead or ball mills can be utilized to 
prepare a nanocrystal formulation. In this method, the active drug substance and the 
stabilizer are dispersed in the dispersion medium, and this mixture is then put into a 
grinder chamber. Balls are rotated at a very high speed and particle size of the drug 
gets smaller until nanocrystals are obtained. 
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Physicochemical characteristics of the nanocrystals depend on the number of 
milling balls, the amount of drug and stabilizer, milling time and speed, type of 
grinding chamber and temperature. In contrast with high pressure homogenization, it 
is a low energy technique. Grinder chambers are made from stainless steel, porcelain 
or hard material, and the balls are made from porcelain, glass, zirconium oxide, 
stainless steel, chromium, agate, or special polymer materials. The type of material 
that the balls are made of is very important since an interaction could take place 
between the material and the drug substance. In this regard, agate balls are frequently 
used in the pharmaceutical field as the possibility of such an interaction is minimized. 
Another important factor is the size of balls. When the balls with small diameter are 
used, grinding time is extended but smaller particles are obtained. 
The mechanism of ball milling is that while grinding chamber is rotated, balls 
are rotated too, and at the end of this procedure, the particle size of the active drug 
substance is reduced by mechanical energy. Thus, particle size of active drug 
substances can be adjusted by changing the diameter and number of balls. Rotational 
speed of the grinding chamber is also very important. If the rotational speed is too 
low, balls cannot rotate effectively and grinding cannot be done efficiently. If 
rotational speed is very high, balls will remain at the edge of the grinding chamber 
due to centrifugal forces and grinding cannot bed one effectively. Moreover, for 
efficient grinding the volume of the balls should be 30 % to 50 % of the grinding 
chamber. The milling time depends on many factors such as the surfactant content, 
hardness of the drug, viscosity, temperature and energy input. The milling time can 
change from 30 minutes to hours or several days.  
The main problem in this method is the contamination of the product as a 
result of erosion of balls or grinding chamber. Therefore, grinding time and the 
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material of balls/grinding chamber should be selected very carefully. This interaction 
can be reduced by using surface active agents or polymers (Tugba Gulsun et al., 
2010). 
Commercial products from this method include Rapamune1, Emend1, 
Tricore1, Megas ES1 and Invega1 (Huabing Chen et al., 2011). 
3. Top down and bottom up technology 
In “top down and bottom up” technology, both methods are used together. 
NanoEdge
®
 is a product obtained by such a combination technology. As can be 
inferred, precipitation is followed by high pressure homogenization in this technology 
(Tugba Gulsun et al., 2010). 
PROCESSING OF NANOSUSPENSION TO FORM NANOCRYSTALS (Sanjay 
Bansal et al., 2012). 
The nanonization of drugs by various techniques generally results in a liquid 
product called nanosuspension. But these nanosuspensions are directly used as a final 
product only in some special cases e.g. as pediatric or geriatric dosage forms. In most 
of the cases, a dry dosage form (particularly for oral administration) is preferred, may 
be 
a. for convenience, 
b. to achieve a controlled drug delivery, 
c. to prevent drug degradation, 
d. to enable better drug targeting, 
e. to increase the physical stability for long term storage and 
f. to obtain a fine non-aggregated suspension in the gastro-intestinal tract after 
oral administration. 
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In such cases, the nanosuspension needs to be transformed into solid forms, 
which may be crystalline (Nanocrystals) or amorphous (Nanomorphs). Various 
techniques are used for this purpose like spray drying, freeze drying, pelletization or 
granulation. 
1. Spray Drying 
One of the preparation methods of nanocrystals is spray drying. This method 
is usually used for drying of solutions and suspensions. In a conical or cylindrical 
cyclone, solution droplets are sprayed from top to bottom, dried in the same direction 
by hot air and spherical particles are obtained. Spraying is made with an atomizer 
which rapidly rotates and provides scattering of the solution due to centrifugal effect. 
The solution, at a certain flow rate, is sent to the inner tube with a peristaltic pump, 
nitrogen or air at a constant pressure is sent to the outer tube. Spraying is provided by 
a nozzle. Droplets of solution become very small due to spraying; therefore, surface 
area of the drying matter increases leading to fast drying. Concentration, viscosity, 
temperature and spray rate of the solution can be adjusted and particle size, fluidity 
and drying speed can be optimized. The dissolution rate and bioavailability of several 
drugs, including hydrocortisone, COX-2 Inhibitor were improved utilizing this 
method. 
2. Freeze drying  
Another method for removing water from formulation is freeze drying. This 
however, is a complex and expensive process and the product obtained is highly 
sensitive to process parameters. This method is not suitable for industrial production.  
A new technique based upon freeze drying was developed by de Waard. In 
this technique a mixture of the drug, solvent, and mannitol is cooled rapidly, resulting 
in separation of drug in a nanocrystal form encased by a matrix of mannitol. 
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This matrix increases the stability of the nanocrstallized drug without which 
the crystals may stick together and form one large crystal. De Waard also developed a 
spray-freeze-drying method which enables the process to be applied on an industrial 
scale. Another method developed by the same author was a spray-freeze-drying 
method which could make industrial application of this process simpler. 
Lyophilization of drug nanoparticles produced in water-reduced media can be 
used to produce FDDS (Fast Dissolving Drug Delivery Systems). For parenteral 
application Nanopure can be lyophilized and reconstituted prior to injection with 
isotonic media (e.g. water with glycerol). 
3. Pelletization   
 A number of pelletization techniques are known, but the most commonly used 
techniques are a) extrusion-spheronization and b) drug coating onto sugar spheres. 
The pelletization technique is selected on the basis of the required drug content, 
properties of the drug and the available equipment. A multi-particulate dosage form 
such as coated pellet system is obtained irrespective of the pelletization technique 
applied. These multi-particulate dosage forms show distinct advantages over single 
unit dosage forms such as faster and more predictable gastric emptying and more 
uniform drug distribution in GIT within different individuals. 
a) Production of pellets containing drug nanocrystal-loaded matrix cores 
 The drug nanosuspension obtained by high-pressure homogenization is mixed 
with matrix material (fillers such as MCC, Lactose or Starch). Pellets are produced by 
extrusion-spheronization and can be subsequently coated with polymers to modify the 
drug release properties. Mucoadhesive budenoside nanocrystals were prepared using 
extrusion-spheronization. The obtained pellets were coated with Eudragit L 30 D- 55 
to obtain enteric coating and delayed drug release . Another type of modified release 
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pellet formulations containing ibuprofen drug nanocrystals were produced by HPH. 
These ibuprofen containing pellets loaded with nanocrystals of the drug dissolved 
completely within 30 minutes from both formulations. 
Spray coated pellets of hydrocortisone acetate were prepared (enteric coated) 
from mucoadhesive nanosuspension of this poorly soluble drug. The invitro 
dissolution tests showed an accelerated dissolution rate and an increased drug release 
for the pellets containing drug nanocrystals. 
b) Production of pellets by Nanosuspension layering onto sugar cores:  
The drug nanosuspension obtained by HPH is directly layered onto sugar 
beads and subsequently coated with polymers using the same equipment to modify the 
drug release properties.  
SELECTION OF STABILIZERS FOR NANOCRYSTAL PREPARATION 
 Selection of stabilizers is very important in nanocrystal formulations because 
the type and concentration of stabilizer affect the final size of the particles, and also, 
stabilizers prevent nanocrystals from aggregating. Polymers or surface active agents 
exert their effect by covering the surface of drug nanocrystals and providing 
stabilization by creating a steric barrier. At the nano size, forces between particles due 
to dispersion or van der Waals forces come into play. Nanosized particles with a high 
surface area have high surface free energy (ΔG). Thus, particles tend to agglomerate 
in order to decrease the surface free energy leading to an increase in particle size and 
reduction in the surface area. Therefore, a stabilizer leads to a decrease in ΔG by 
decreasing the interfacial tension γs/l.  
ΔG=ΔA•γs/l 
γs/l: interfacial tension between the surface of solid and the surrounding liquid 
phase (joule/m2) 
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ΔG: change in surface free energy (joule) 
ΔA: change in the surface area (m2) 
Jonghwii Lee and coworkers have reduced the particle size of seven different 
active drug substances by preparing nanocrystals. They investigated two different 
stabilizers (polyvinylpyrollidone and hydroxypropyl cellulose), their interaction with 
the active drug substances, and effects on surface energy and particle size. They found 
that interactions between stabilizers and active drug substances were complex and 
depended on many variables, such as presence of functional groups and surface 
energy. The concentration of the stabilizer is an important factor that affects the 
physical stability of the final product. 
  Hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), 
povidone (PVP K30), and pluronics (F68 and F127) are polymers suitable for use as 
stabilizers. The chains should be long enough to provide a steric layer, but not too big 
to slow down dissolution. Polysorbate 80 (nonionic), sodiumlaurylsulfate (SLS) and 
docusate sodium (DOSS) (both anionic) are some examples of suitable surfactant 
stabilizers for physical stability. Also, surfactants often help in the wetting, 
electrostatic stabilization and dispersion of the drug particles, which are usually very 
hydrophobic. HPMC E3, Povidone, DOSS, and SLS are some of the stabilizers that 
have been used in the nanocrystal formulations of drugs that are on the market today 
(Tugba Gulsun et al., 2010). 
CHARACTERIZATION AND EVALUATION OF NANOCRYSTAL 
SUSPENSIONS(Lei Gao et al., 2008) 
The essential characterization parameters for nanocrystal suspensions are as 
follows: 
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a) Size and size distribution 
Size and size distribution are important characterizations of the 
nanosuspensions because they govern the other characterizations, such as saturation 
solubility and dissolution velocity, physical stability, or even biological performances. 
The mean particle size of nanosuspensionsis typically analyzed by photon correlation 
spectroscopy (PCS). Apart from the mean particle diameter, PCS can also yield the 
width of the particle size distribution, i.e. polydispersity index (PI). The PI value 
ranges from 0 (monodisperse particles) to 0.500 (broad distribution), and is an 
important index that governs the physical stability. For a long-term stability the PI 
should be as low as possible. 
However, due to a narrow measuring range of PCS, approximately from 3 nm 
to 3 lm, it shows an incapability in the detection of the larger microparticles. Then the 
laser diffractometry (LD) is needed to investigate the content of particles in the 
micrometer range or aggregates of drug nanoparticles, especially for the 
nanosuspensions that are meant for parenteral and pulmonary delivery. The LD yields 
a volume distribution and possesses a measuring range of approximately 0.05–80 lm 
up to a maximum of 2000 lm, depending on the type of equipment employed. Typical 
characterization parameters of LD are diameters 50%, 90%, 99% represented by D50, 
D90 and D99 respectively (i.e. the D50 means that 50% of the volume of the particles 
is below the given size). 
A Coulter counter analysis is essential for nanosuspensions to be administrated 
intravenously. Compared with a volume distribution of the LD analysis, the Coulter 
counter data give an absolute value, that is the absolute number of particles per 
volume unit for the different size classes. The size of the smallest blood capillary is 
about 5 lm, so even a small content of particles greater than 5 lm may cause capillary 
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blockade or emboli formation. So the content of microparticles in nanosuspensions 
should be controlled strictly by Coulter counter analysis. 
b) Shape and morphous 
Typically, the shape or the morphous of the nanocrystals can be determined 
using a transmission electron microscope (TEM) and/or a scanning electron 
microscope (SEM). A wet sample of suitable concentration is needed for the TEM 
analysis. When the original nanosuspensions are required to be processed into dried 
powder (e.g. by spray drying or lyophilization), a SEM analysis is essential to monitor 
changes of the particle size before and following the progress of the water removal. In 
general, agglomeration phenomenon may occur following water removal, leading to 
an increase of the particles’ size which can be viewed through SEM. To minimize the 
extent of the increase of particle size, some excipients should be added as a protectant. 
For example, mannitol, generally used as a cryoprotectant in lyophilization, can 
recrystallize around nanocrystals during the water-removal operation, thus preventing 
particle interaction and agglomeration. An agglomeration within a certain extent is 
permitted when the particle size still in an accepted range, particularly the dried 
powder can be well redispersed into stable nanosuspensions. The shape of the drug 
crystals depends on their crystalline structure; different crystal shapes of different 
drugs were viewed under SEM. 
c) Zeta potential 
 The measurement of the zeta potential allows the prediction about the storage 
stability of submicron colloidal dispersion. In general, particle aggregation is less 
likely to occur if particles possess enough zeta potential providing sufficient electric 
repulsion, or enough steric barrier providing sufficient steric repulsion between each 
other. According to the literature, a zeta potential of at least -30 mV for electrostatic 
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and -20 mV for sterically stabilized systems is desired to obtain a physically stable 
nanocrystal suspensions. 
d) Crystalline state 
 The evaluation of crystalline state is necessary to understand the polymorphic 
changes that a drug might undergo when subjected to nanosizing. Differential 
scanning calorimetry(DSC) and X-ray diffraction can be used to evaluate the 
crystalline structure of the drug nanocrystals. It was reported that some drugs retained 
their crystalline state during homogenization, example  danazol and nifedipine. 
However, for some drugs, for example azithromycin, the results of DSC and X-ray 
showed that amorphous state was generated during homogenization. Though it 
increases the saturation solubility, the amorphous state is a metastable state with a 
higher energy and leads to an instability during shelf time. Transforming the 
nanosuspension into stable dried solid powder by water removal can resolve this 
problem. 
e) Saturation solubility and dissolution velocity 
Determination of the saturation solubility and dissolution velocity is very 
important as it not only can help to assess the benefits compared to the microparticle 
formulation but also help to anticipate the in vivo performance (e.g. blood profiles, 
plasma peaks, and bioavailability). The nanosuspensions should be transferred into a 
dried powder before the investigation of the dissolution behavior. In the shakering 
experiments a different temperature can be used to determined the saturation 
solubility of a dried powder in a different artificial medium (i.e. physiologic saline, 
artificial gastric juice, or artificial intestinal juice). To determine the dissolution 
velocity,the methods described in the Pharmacopoeia can be used; also experiments in 
various physiological buffers should be performed. 
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f) Surface properties   
The research on the surface parameters of nanosuspensions is very important, 
especially for the nanosuspensions to be administrated intravenously. The fate of the 
nanocrystals in vivo following injection, such as organ distribution, depends on its 
surface properties, such as surface hydrophobicity and interactions with plasma 
proteins. Therefore, some special techniques have to be used to evaluate the surface 
properties to give an idea of in vivo behavior. Hydrophobic interaction 
chromatography has been used to determine the surface hydrophobicity, and 2-D 
PAGE can be performed to measure the protein absorption after intravenous injection 
of nanosuspensions. 
APPLICATIONS OF NANOCRYSTALS BY VARIOUS ROUTES OF 
ADMINISTRATION 
a) Drug Nanocrystals for Oral administration  
Enhancement in bioavailability of poorly soluble drugs after oral 
administration. Besides it has also been proved by various drug nanocrystal products 
placed in the market. A faster onset of action and decreased gastric irritancy has been 
reported when naproxen was formulated as nanosuspension. Due to fast dissolution of 
nanocrystals, the drug solubility is enhanced, making it bioequivalent in fed and 
fasting conditions. The bioadhesive nature of nanocrystals offers additional advantage 
of increased stay in the gastro-intestinal tract which enhances bioavailability. The  
nano size can be exploited for better drug targeting as reported for lymphatic drug 
uptake or for inflammatory tissues. Nanosuspensions can be formulated as more 
concentrated and less viscous. Patient has to take lesser dose of easily swallowed 
formulation (e.g. Megace ES). Nanoparticles provided sustained release of anti-
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tubercular drugs – rifampin, isoniazid and pyrazinamide and considerably improved 
their efficacy after oral administration (Sanjay Bansal et al., 2012). 
b) Parenteral Administration of Drug Nanocrystals 
The parenteral application of poorly soluble drugs, particularly intravenous 
(IV) administration of practically insoluble compounds, using cosolvents, surfactants, 
liposomes, or cylcodextrines, is often associated with large injection volumes or toxic 
side effects. Carrier-free nanosuspensions enable potential higher loading capacity 
compared to other parenteral application systems. Using nanosuspensions, the 
application volume can be distinctly reduced compared to solutions. To fulfil the 
distinctly higher regulatory hurdles, the drug nanocrystals need to be produced in an 
aseptic process. Alternatively, nanosuspensions can be sterilized by autoclaving or 
alternatively by gamma irradiation as well as sterile filtration. When a drug is 
administered as a nanosuspension, the rapid dissolution of the nanocrystals will mimic 
the plasma concentration profile of a solution. Drug nanosuspensions can be 
formulated with accepted surfactants and polymeric stabilizers for IV injection. In 
contrast, solutions of poorly soluble drugs require the use of cosolvents and/or high 
surfactant contents (e.g., Chremophor EL in Taxol
®
), which can cause undesired side 
effects (Suman Katteboinaa et al., 2009). 
c) Drug Nanocrystals for Pulmonary drug delivery  
 Poorly soluble drugs can be delivered directly to the lungs by nebulizing the 
aqueous nanosuspensions using mechanical or ultrasonic nebulizers. Using 
nanoparticles, drug is more evenly distributed in droplets. All aerosol droplets are 
likely to contain drug nanocrystals. Budenoside, poorly water soluble corticosteroid, 
has been successfully prepared as a nanosuspension for pulmonary delivery. It 
showed long term stability. No particle growth and aggregates formed over a period 
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of one year. In addition, Buparvaquone nanosuspension was formulated for an 
alternative treatment of lung infection (pneumonia) to deliver the drug at the site of  
lung infection using nebulization. Administration to infected guinea pigs of nebulized 
rifampin, isoniazid and pyrazinamide encapsulated in wheat germ agglutinin 
functionalized PLG nanoparticles was much more effective. Three doses administered 
fortnightly for 45 days were sufficient to produce a sterilizing effect in lungs and 
spleen. Drug nanocrystals showed an increased mucoadhesiveness leading to a 
prolonged residence time at the lung mucosa (Sanjay Bansal et al., 2012). 
d) Drug Nanocrystals for Ophthalmic Drug Delivery 
It could be shown that nanoparticles possess a prolonged retention time in the 
eye, most likely due to their adhesive properties. From this, poorly soluble drugs 
could be administered as a nanosuspension. The development of such colloidal 
delivery systems for ophthalmic use aims at dropable dosage forms with a high drug 
loading and a long-lasting drug action. The nanosuspensions were prepared by a 
modification of the quasi-emulsion solvent diffusion technique using variable 
formulation parameters (drug-to-polymer ratio, total drug and polymer amount, 
stirring speed). Nanosuspensions had mean sizes around 100 nm and a positive charge 
(zeta-potential of +40/+60 mV), this makes them suitable for ophthalmic applications. 
Stability tests (up to 24 months storage at 4 degrees C or at room temperature) or 
freeze-drying were carried out to optimize a suitable pharmaceutical preparation. In 
vitro dissolution tests indicated a controlled release profile of IBU from nanoparticles. 
In vivo efficacy was assessed on the rabbit eye after induction of an ocular trauma 
(paracentesis). An inhibition of the miotic response to the surgical trauma was 
achieved, comparable to a control aqueous eye-drop formulation, even though a lower 
concentration of free drug in the conjunctival sac was reached from the nanoparticle 
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system. Drug levels in the aqueous humour were also higher after application of the 
nanosuspensions; moreover, IBU-loaded nanosuspensions did not show toxicity on 
ocular tissues. 
e) Drug Nanocrystals for Dermal Drug Delivery 
  Dermal nanosuspensions are mainly of interest if conventional formulation 
approaches fail. The use of drug nanocrystals leads to an increased concentration 
gradient between the formulation and the skin. The increased saturation solubility 
leads to supersaturated  formulations, enhancing the drug absorption through the skin. 
This effect can further be enhanced by the use of positively charged polymers as 
stabilizers for the drug nanocrystals. The opposite charge leads to an increased 
affinity of the drug nanocrystals to the negatively charged stratum corneum (Suman 
Katteboinaa et al., 2009). 
f) Drug Nanocrystals for Targeted drug delivery 
Nanocrystals can have deep excess to the human body because of particle size 
and control of surface properties. So they can also be used for targeted drug delivery. 
Kayser  developed a nanosuspention of aphidicolin to improve drug targeting against 
Leishmania-infected macrophages. He demonstrated that aphidicolin was highly 
active at a concentration in the microgram range. Similarly peptide dalargin was 
successfully targeted to the brain by employing surface modified poly(butyl) 
cyanoacrylate nanoparticles. Nanoparticles offer a promising new cancer treatment 
that may one day replace radiation and chemotherapy. Kangius RF therapy attaches 
microscopic nanoparticles to cancer cells and then cooks tumors inside the body with 
radio waves that heat only the nanoparticles and the adjacent cancerous cells. Muco-
adhesive pellets or nanoparticles have been used as specific carrier systems for oral 
administration. 
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Bupravaquone nanosuspension was successfully used for targeting of 
Cryptosporidium parvum, (the organism responsible for cryptosporidium) by altering 
the mucoadhesive properties. Amphoterecin B as pulmonary nanosuspension was 
used to target conditions such as pulmonary asperigillosis (Sanjay Bansal et al., 
2012). 
PRODUCTS IN THE MARKET 
All nanocrystals in the first four products were produced using the pearl mill 
technology by Elan Nanosystems. Prerequisite was the availability of production 
facilities at sufficiently large scale. In general candidates of first choice for 
Nanocrystal
®
 technology are drugs with a relatively low dose. 
a) Rapamune
®
 
Rapamune
®
 contains sirolimus (SRL, rapamycin) as the active drug, which is 
derived from Streptomyces hygroscopicus (actinomycetes) (Figures 6). SRL is a 
macrocyclic immunosuppressive drug with a molecular weight of 914.2 and is related 
to tacrolimus which is produced from different species of Streptomyces. 
SRL is being used mostly in a combination with cyclosporine or steroids to 
avoid organ rejection in patients after a kidney transplant. In cardiology SLR is used 
because of its antiproliferative effect to avoid a reoccurring constriction (restenosis) 
caused by a hyperplasia of the inner vascular after implantation of a stent into the 
vessels around the heart.  
Rapamune was the first marketed product introduced in 2000 by Wyeth 
Pharmaceuticals. It is available in two formulations, as oral suspensions and as a 
tablet. The tablet  has the advantage of being more user friendly. Comparing the oral 
bioavailability of solution and nanocrystal tablet, the bioavailability of the 
nanocrystals is 21% higher compared to the solution. The oral single dose of 
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Rapamune is 1 or 2 mg, the total tablet weight being approximately 365 mg for 1 mg 
formulation and approximately, 370 mg for the 2 mg formulation. This means it 
contains a very low percentage of its total weight as nanocrystals. An important point 
is that the drug nanocrystals are released from the tablet as ultra fine nanosuspension. 
In the event that crystal aggregation takes place to a pronounced extent, the 
dissolution velocity and subsequently the oral bioavailability of the BSC II drugs will 
be reduced. Therefore, there is an upper limit to load tablets with nanocrystals. In case 
the limit is exceeded and nanocrystals get in contact with each other within the 
excipient mixture of the tablet, the nanocrystals might fuse to larger crystals under the 
compression pressure during tablet production. For drugs with a low oral single dose 
such as sirolimus in Rapamune, incorporation into tablets causes few or no problems. 
A total nanoparticle load of less than 1% is well below the percentage being critical. 
The main advantages of the nanocrystal technology in this product are the user 
friendliness and the higher bioavailability in comparison to the oral solution. As 
discussed previously, a smaller particle size leads to greater solubility and larger 
surface area, consequently increased dissolution velocity and thus greater 
bioavailability. 
 
FIGURE 6: PACKAGING OF RAPAMUNE
® 
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b) Emend
®
 
The second product on the market was Emend
®
, introduced in 2001 by Merck 
(Winehouse Station, NJ) (Figures 7). The drug is aprepitant, used for treatment of 
emesis (single dose is either 80 or 125 mg). 
 
FIGURE 7: PACKAGING OF EMEND
®
 
Aprepitant will only be absorbed in the upper gastrointestinal tract. Bearing 
this in mind nanoparticles proved to be ideal to ideally exploit this narrow absorption 
window. The large increase in surface area due to nanonization leads to rapid in vivo 
dissolution, fast absorption and increased bioavailability. The formulation of a tablet 
from micronized bulk powder made much higher doses necessary, leading to 
increased side effects (eg, other serotonin receptor induced effects like dizziness).  
The drug nanocrystals are contained within a hard gelatin capsule as pellets. 
Aprepitant was formulated this way in order to make the drug easy to handle by 
healthcare providers and patients as capsules. In addition, the pellets can be 
administered via a stomach tube. Currently studies are being undertaken to evaluate 
the change in pharmacokinetics (if any) between the pellets and the capsules. One 
needs to bear in mind that a higher loading of the tablet with more than 125 mg drug 
in a 400 mg tablet is near the critical amount, which is about 30%. If the total drug 
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content exceeds 30%, the possibility of drug nanocrystals directly touching each other 
and fusing to larger crystals is enhanced. There are special methods and technologies 
required to produce high nanocrystal-loaded tablets. By applying this, up to 90% 
nanocrystal powder would be loaded into tablets. 
This example of aprepitant demonstrates once again the importance of an 
increased bioavailability through nanonization. In case of a drug with a narrow 
absorption window which is also poorly soluble it is important to reduce the particle 
size to a size threshold that will make the drug bioavailable by enhancing the 
solubility. 
c) Tricor
®
 
Tricor
®
 is being marketed by Abbott Laboratories and the active ingredient is 
fenofibrate, being available in 48 mg and 145 mg tablets (Figures 8). Tricor is 
indicated as adjunctive therapy to diet in adult patients with primary 
hypercholesterolemia or mixed dyslipidemia to increase high-density lipoprotein 
cholesterol (HDL-C), reduce triglycerides (TG), reduce low-density lipoprotein 
cholesterol (LDL-C), reduce total cholesterol (Total-C), and reduce apolipoprotein B 
(Apo B). 
Fenofibrate is a lipophilic compound and practically insoluble in water. 
Having no ionizable group, the solubility of fenofi brate was not infl uenced by 
changes in pH value through the application of food. The enhanced absorption of 
fenofibrate in fed patients can be explained with the availability of lipids and other 
surfactants (eg, cholesterol) in the food, thus solubilizing the fenofibrate. By 
nanonizing the drug, the solubility is enhanced, making it bioequivalent in fed and 
fasting conditions. 
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FIGURE 8: PACKAGING OF TRICOR
®
 
Another product using nanocrystals to make an advanced fenofibrate is 
Triglide®, which is produced using the IDD-P
®
-technology (as discussed before) 
from Skye pharma and is marketed by Sciele Pharma Inc. 
d) Megace ES
® 
In Megace ES
® 
(ES stands for Enhanced Stability) (megestrol acetate) 
introduced by Par Pharmaceutical Companies, Inc., who licensed the Megace name 
from Bristol-Myers Squibb (New York, NY), the Nanocrystal technology leads to 
several advantages (Figures 9). 
Megestrol is mainly used to improve weight gain and appetite in patients 
undergoing chemotherapy or suffering from an HIV infection. It can also be used to 
treat psychologically induced anorexia. The precise mechanism of megestrol’s 
antianorexic and anticachetic effects is unknown. 
Megestrol is well absorbed in the gastrointestinal tract but absorption varies. A 
bioavailability study comparing the peak plasma concentration and extent of 
absorption of Megace ES and megestrol acetate oral suspension revealed that in unfed 
patients, the bioavailability of Megace ES is minimally reduced while there was a 
substantial food effect for megestrol acetate oral suspension. 
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FIGURE 9: PACKAGING OF MEGESTRAL
 
The improved rate of dissolution again resulting from the particle dimensions 
in the nanometer range leads to an enhanced bioavailability in people in fasted state. 
The nanonized drug can be formulated in less volume, so the single dose the 
patient has to take (daily dose 625 mg of megestrol in 5 ml of fl uid) is reduced by the 
factor four compared to the oral solution available. This reduced volume and the 
improved bioavailability lead to a better patient compliance due to the possibility of  
flexible dosing in order to provide effective appetite stimulation and weight gain. 
Another advantage is the reduced viscosity of the Megace ES formulation, 
which also leads to increased patient compliance. This viscosity reduction is a direct 
effect of the reduction of the particle size (no or little viscosity enhancement 
necessary to prevent sedimentation) (Rainer Muller. H et al., 2008). 
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CHAPTER-III 
LITERATURE REVIEW 
Chaudhar Bharat et al., 2013, enhanced the solubility and dissolution rate of 
Albendazole, a class II drug, by two different techniques, and compared them for 
improved drug delivery study. These techniques were inclusion complex of 
Albendazole with Hydroxypropyl-β cyclodextrin (HP- β-CD), and, converting drug 
into nanocrystal formulation by anti solvent precipitation techniques in the presence 
of Sodium  Lauryl Sulfate (SLS) as stabilizers. The drug inclusion complex with HP- 
β-CD were prepared by Kneading method  with different ratio of HP- β-CD. Finally, 
it was concluded that, Amongst these formulation techniques, Nanocrystalization 
techniques found to be more effective than inclusion complex with HP-β-CD 
Abdul Hasan Sathali.A., and Gopinath.M., et al., 2013, developed Paliperidone 
nanocrytal in order to enhance the solubility and dissolution rate by decreasing the 
particle size of the drug and also sustained the drug release profile by using Eudragit 
L100 as polymer at different ratio. The Paliperidone nanocrystals were successfully 
prepared by nanoprecipitation method using different stabilizers (PVP K30, 
Poloxamer 1888, Poloxamer 407, combination of PVP K30 and Poloxamer 407,  
combination of PVP K30 and poloxamer 188). The formulations were evaluated for 
entrapment efficiency, morphology, size distribution, zeta potential, solubility studies 
and stability studies. The presence of stabilizers made the nanocrystal formulation 
more stable. The solubility studies and invitro dissolution studies suggested that the 
CHAPTER-III                                                                         LITERATURE REVIEW 
 
Ramipril Nanocrystals Reg No: 261211301 Page 41 
 
nanocrystal formulations can improve the bioavailabilty of paliperidone when 
compared to pure drug. The X-ray powder diffraction (XRPD) confirmed that, there 
was no change in the crystalline state by this size reduction process. Stability studies 
were favourable for the development of this nanocrystal formulations. 
Raghvendra., and Amlan Mishra., 2013, reviewed on nanocrystal technology in 
different fields, including medicine and pharmacy. Transferred material into 
nanodimension to develop a new innovative formulation for poorly soluble drugs. 
Nanocrystals have a wide variety of proven and potential applications. They have 
been used in the manufacture of filters that refine crude oil into diesel fuel, and, 
applied to flexible substrates to produce solar panels. Nanocrystals were emerged as 
key material due to their novel shape and size dependent chemical and physical 
properties. 
Zuki Abu Bakar Zakaria et al., 2013, synthesized biobased calcium carbonate 
nanocrytals had demonstrated to be an effective carrier for delivery of anticancer drug 
Doxorubicin (DOX). These nanocrystls displayed high levels of selectivity and 
specificity in achieving effective cancer cell death without non-specific toxicity. The 
CaCo3/DOX nanocrystals were relatively stable at neutral pH (7.4), resulting in slow 
release of drug, but, progressively dissociated in acidic pH (4.8) and faster release of 
DOX. They indicated that, CaCo3/DOX nanocrystals were more sensitive and gave a 
greater reduction in breast cancer cell growth by controlled and targeted cancer 
therapy than free DOX. 
Neusin Bolourchain et al., 2013, prepared Clarithromycin (CLA) nanoparticles from 
a  ternary ground mixture in the presence of Sodium Lauryl sulfate(SLS) and 
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Polyvinyl pyrrolidone (PVP) as co-grinding water soluble compounds, in order to 
improve the drug dissolution rate. Different weight ratios of CLA:SLS:PVP were 
ground in a dry process by planetary ball mill using different grinding ball size. This 
formulation formed nanocrystals with enhanced solubility, after dispersing in water. 
X-ray diffraction, differential scanning calorimetry and Infrared spectrophotometry 
confirmed no chemical intraction and phase transition during the process. Accelerated 
stability studies confirmed that the co-ground mixture, remained unchanged in terms 
of dissolution rate, drug assay and particle size. The results revealed that the 
dissolution rate of ternary ground mixtures were much higher than that of the intact 
drug. 
Koichi Baba et al., 2013, prepared steroid nanocrystals using the nano spray dryer B-
90. The particle size was controlled by selecting the mesh aperture size. Submicron 
steroid particles in powder form were successfully obtained. These nanoparticles were 
confirmed to have a crystal structure using powder X-ray diffraction pattern analysis. 
Steroid nanocrystals were dispersed in aqueous solution and attractive as nanocrytals 
based eye drop solution for the treatment of Ophthalmic disorders in the near future. 
Sanjay Bansal et al., 2012, studied a large number of drugs have been discovered, 
which have a better efficiency but their clinical application is restricted due to poor 
water solubility. Poor water solubility has become a leading challenge for the 
formulation of these compounds. Poor solubility is generally associated with poor 
bioavailability. Nanocrystal have the potential to overcome this issue. Drug 
nanocrystals are crystals with the size in the nanometer range (mean diameter < 
1000nm). 
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Shailesh Soni et al., 2012, reviewed on nanosuspension contain submicron colloidal 
dispersion of pharmaceutical active ingredient particles in a liquid phase stabilized by 
surfactants. The poor water solubility of drug was major problem for drug 
formulation. The reduction of drug particles into the submicron range leads to a 
significant increase in the dissolution rate, bioavailability as well as improve stability. 
Nanosuspension consists of the pure poorly water soluble drug without any matrix 
material suspended in dispersion. Nanosuspension prepared by various methods such 
as media milling and high pressure homogenization have been used commercially, 
recently nanosuspensions were prepared by employing emulsion solvent diffusion 
method and microemulsion as templates. 
Dianrui Zhang et al., 2012, magnified the clinical use of Amoitone B, by nanocrystal 
technology, in order to solve the poor solubility and dissolution rate problems. 
Optimized Amoitone B nanocrystal with small and uniform particle size were 
successfully prepared by microfluidization method. And investigated by morphology, 
size distribution, and zeta potential. The differential scanning calorimetry(DSC) study 
and X-ray diffraction (XRD) confirmed, there was no crystalline state changed in the 
size reduction process. Finally concluded that, developed Amoitone B nanocrystal not 
only increased saturation solubility, but also reduced its side effects, and expected to 
choice for intravenous delivery and further application to cancer therapy. 
Dianrui Zhang et al., 2012, compared, different methods for preparation of stable 
riccardin  D formulation by nano-technology. Nanocrystals were prepared in the 
evaporative precipitation into aqueous solution (EPAS) and the microfluidisation 
process. The characterizations of nanocrystals were compared by transmission 
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electron microscope, size distribution and zeta potential. Poloxamer 188, hydroxyl 
propyl methyl cellulose, PVP k30 were used as surfactant and polymers. The 
nanocrystals made in EPAS process were smaller, more uniform and had a narrow 
distribution than the microfluidisation nanocrystals. Differential scanning calorimetry 
and X-ray diffraction confirmed the crystalline states that were both reserved. The 
solubility were greatly improved by the two methods and the EPAS nanocrystals were 
more stable due to the smaller size. The stable nanocrystals were successfully 
achieved by the two methods. 
Fude Cui et al., 2012,  modified the nitrendipine nanocrystals surface with negative 
charge to improve bioavailability. The nanocrystals were prepared via precipitation 
high pressure homogenization method. The nanocrystal were dispersed into chitosan 
solution, the free chitosan was removed by centrifugation method to obtain the 
chitosan modified nanocrystal. The physical stability of the preparation was improved 
under ambient condition. During invitro drug release, nanocrystal showed slow 
release property. The surface modification by chitosan improved the bioavailability 
compared with initial nanocrystal. The intraction between the negatively charged 
nitrendipine nanocrystals and the positively charged chitosan, the particle size 
stability was increased. 
Jiao Sun et al., 2012, prepared nanocrystals, without any surfactant or polymer using 
the solvent/nonsolvent method. The effect of size on their solubility, dissolution and 
oral bioavailability were investigated. A precipitation method was developed for 
producing suspension of naked coenzyme Q10 nanocrystal. The nanocrystal 
suspension was concentrated by ultrafiltration method. The particle effect on 
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dissolution was clearly influenced by the diffusion coefficients of the various 
dissolution media. For particle size 700nm nanocrystals, he AUC0-48 was 4.4 fold 
greater than that for the coarse suspension. But further the particle size was reduced to 
80nm, the bioavailability was increased by 7.3 fold. 
Maiti S et al., 2012, studied liquid-crystal and nanocrystal technology for 
solubilization of poorly water soluble drugs. Any  material with a dimension of less 
than 1 micrometer ie 1000nm, should be referred to as a nanoparticles, not a 
nanocrystal. Crystalline nanoparticles are often provide single domain crystalline 
system that can be studied to provide information, that can be help to explain the 
behavior of macroscopic samples of similar material. Nanocrystal is also a registered 
trademark of Elan Pharma International Ltd(Ireland). That improves the 
bioavailability of drugs by nanoscale particles, that can be suspended in liquid, made 
into powder, pressed into tablets or encapsulated. As decreased size of the drug 
particles, may increase oral bioavailability of sparingly water soluble drugs. Drugs 
nanocrystals can be used for chemical stabilization of chemically labile drugs. The 
increased stability can be explained by a shield effect of the surfactant. 
Filippos kesisoglou et al., 2012, studied, nanosuspension formulations of crystalline 
active pharmaceutical ingredients (API) with particle size in the submicron range, 
have been shown to increase oral bioavailability of compounds. Their ability to 
increase the oral bioavailability has been demonstrated in preclinical and clinical 
settings. 
Siling Wang et al., 2012, revealed that, many drugs are abandoned early in discovery 
due to extremely low solubility in both aqueous and non-aqueous solvent. As 
CHAPTER-III                                                                         LITERATURE REVIEW 
 
Ramipril Nanocrystals Reg No: 261211301 Page 46 
 
traditional formulation strategies fail to solve the intractable issue, there comes to 
drug nanocrystal regarded as universal, simple and industrially feasible. It includes 
buttom up method (Anti solvent precipitation, supercritical fluid process, spray 
drying) top down method(pearl milling, high pressure homogenization, combination 
technologies) and the latest second generation nanocrystals technologies, related 
physical instabilities(Sedimentation, agglomeration, crystal growth, and crystalline 
state conversion) and the methods to alleviate or tackle the stability problems are 
discussed. Oral and parenteral administration are two main applications of drug 
nanocrystals could enhance the intracellular uptake of macromolecules and protect 
them from denaturation. 
Narendra Chary T et al., 2012, developed controlled release micropellets dosage 
form of Ramipril. The prototype formulation of micro pellets were prepared by using 
the fluid bed coater(FBC) with the air pressure 2.0 bar and spray rate 10-15ml/min. it 
is observed that at high pressure the pellets are breaking. Concerning results of 
prototype preparation of Ramipril the micro pellets were prepared by using HPMC 
Ethyl cellulose polymer as release retardant different concentration. Formulated micro 
pellets showed delayed invitro dissolution behavior, probably due to optimized 
concentration of polymer. 
Yamini Pendyala., and Sudha Talasila., 2012, formulated and evaluated, 
mucoadhesive Ramipril microspheres for its potential use in the treatment of 
hypertension. Ramipril mucoadhesive microspheres four formulations were prepared 
by an emulsion solvent evaporation techniques. Among all the formulation F4 showed 
good dissolution profile with 81% of drug release in 2hours. The results showed a 
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sustained anti-hypertension effect over a longer period of time in case of 
mucoadhesive microspheres, compared to the powder. Finally concluded that, the 
prolonged gastrointestinal resisdence time and slow release of Ramipril resulting from 
the mucoadhesive microsphere. 
Harish Chander et al., 2011., formulated and evaluated, fast dissolving tablets of 
Ramipril using direct compression technique (effervescent) with sodium bicarbonate, 
mannitol, polyvinylpyrrolidone, citric acid. Eight different formulation of Ramipril 
were prepared by using different ratio of NAHCO3: MANNITOL by direct 
compression method. The tablets were characterized by hardness, wetting time, 
weight variation, water Absorption Ratio, In Vitro Drug Release. The batches of all 
formulations, FDT4 batch with sodium bicarbonate: 
mannitol (1:3) showed more release 97.56%  than the other concentration and better 
results. Bioavailability of Ramipril can be increased by formulating it as a Fast 
Dissolving Tablet. 
Phanchaxari M Dandagi et al., 2011, developed, griseofulvin formulation by 
nanocrystallization techniques for the enhancement of solubility and dissolution 
property of the drug. The drug Nanocrystals(NC) were prepared by emulsion solvent 
diffusion method. Two different solvents such as acetone and ethanol and two 
different stabilizers such as β-cyclodextrin and sodium lauryl sulphate(SLS) were 
evaluated in the process. Out of which formulation made of acetone were smaller size 
compared to ethanol. Formulation made by using acetone as solvent also possessed 
better dissolution velocity as compared to formulation prepared using ethanol as 
solvent. 
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Sinico C et al., 2011, developed piroxicam (PRX) orally disintegrating tablets (ODT) 
by using nanocrystal formulation in order to optimize dissolution properties of 
lipophilic, poorly soluble drug. Different nanocrystal formulations were prepared by 
using High pressure homogenization technique and Poloxamer 188 as stabilizer. 
Dissolution study of PRX ODT was compared to that of PRX coarse suspension 
ODT, PRX /Poloxamer 188 physical mixture and bulk PRX samples. Since the 
solubility of the different PRX polymorphic forms increased only slightly from bulk 
PRX (form I) to monohydrated, form II and form III. Finally concluded that the 
improvement in PRX dissolution rate was mainly caused by the increased surface to 
volume ratio due to the submicron dimension of the drug particles. 
Yuan Gao et al., 2011, investigated the potential of oral and pulmonary baicalein 
nanocrystals to enhance the bioavailability. The baicalein nanaocrystal was prepared 
by anti solvent recrystallization techniques followed by high pressure 
homogenization. Invitro characterization was performed including particle size and 
distribution, zeta potential, dissolution, scanning electron microscopy, differential  
scanning after nanocrystal preparation. The mean relative bioavailability of oral 
baicalein nanocrystal was 1.67-fold that of oral baicalein crystal. 
Mukesh S Patil et al., 2011, prepared Simvastatin nanoparticles by nanoprecipitation 
method using a partially water-miscible solvents and the mutual saturation of the 
aqueous and organic phases prior to form a nanosuspension in order to reduce the 
initial thermodynamic instability of the nanoparticles. Because of the self emulsifying 
properties of the methacrylic acid co-polymers, it was possible to prepare aqueous 
dispersion of colloidal size containing upto 30%w/v of Eudragit L100 using methanol 
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as a water miscible solvent with surfactant. Following oral administration in rats 
Simvastatin NP’s provided significant increase in the bioavailability compared to a 
powder suspension formulation. Simvastatin NP’s formulation was superior to 
marketed formulation with respect to invitro dissolution profile and in vivo 
hypolipidimic activity. 
Basavaraj Nanjwade. K et al., 2011, studied design and characterization of 
Lovastatin nanocrystals for solubility and dissolution enhancement. Some of the 
approaches were available for enhancing the dissolution of poorly soluble drugs. 
Nanonisation technique led to more soluble, more biologically available and safer 
dosage form of poorly soluble and bioavailable drugs. Lovastatin nanocrystals was 
formulated using simple precipitation method without using stabilizer or 
surfactant.The nanocrystals with less particle size was obtained with slight change in 
crystallinity. The nanocrystal formulated with acetone and methanol showed higher 
saturation solubility, less particle size, increased dissolution rate then the nanocrystal 
formulated with acetonitrile. 
Suganeswari. M et al., 2011, formulated the nanoparticles containing atorvastatin 
calcium and amlodipine besylate using nanoprecipitation technique with Pluronic F 
68 and PLGA polymers. The prepared nanoparticles were characterized by particle 
size analysis, drug entrapment efficiency and in vitro drug release studies. The results 
concluded that the improvement in absorption rate, therapeutic efficacy and 
bioavailability of amlodipine and atorvastatin calcium. 
Jingling Tang et al., 2011, improved the oral bioavailabilty of genistein, by 
nanoparticles. Nanoparticles were prepared by the nanoprecipitation technique using 
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Eudragit E100 as carrier. The drug loaded nanoparticles were spherical on observation 
by transmission electric microscopy(TEM). Release of drug from the genistein 
nanoparticles was two times greater than that from the conventional capsules. These 
results suggested that a nanoparticle system was a potentially promising formulation 
for the efficient delivery of poorly water soluble drugs by oral administration. 
Doaa Ahmed El-Setouhy et al., 2011, prepared itraconazole(ITZ) crystalline 
nanoparticles by using sonoprecipitation technique, in which both the solvent and 
antisolvent were organic in nature. The effect of stabilizer type(HPMC,HPC,Inutec 
SPI®, and Pluronic F127) drying method (oven and freeze drying) and matrix former 
used (Avicel PH101 and Aerosil® 200) on the dissolution performance as a key 
characteristic of nanocrystal was evaluated. Freeze  dried ITZ nanocrystals containing 
Avicel PH101 showed better dissolution rate, when compared to other nanocrystals. 
Both inutec SPI® and Pluronic F127 were effective in preserving the rapid drug 
dissolution after 3 months of storage under different conditions. 
Wei Wu et al., 2011, prepared silymarin glyceryl mono oleate/ poloxamer 407 liquid 
crystalline matrices (GMO/P407 LCM) to improve the oral bioavailability of 
silymarin. The silymarin GMO/P407 LCMs were prepared by a melting/ congealing 
method. The isotropic phenomenon observed under polarized light microscope 
confirmed the liquid crystalline structure at the junction of LCM and water. Most 
importantly a 3.5 fold increase in silymarin oral bioavailability as compared with 
Legalon® a commercial silymarin formulation. 
Ming Thau sheu et al., 2011, formulated insitu formation of fenofibrate(FEB) 
nanocrystal from a self-microemulsifying drug delivery system to enhance oral 
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bioavailability.  SMEDDS were formulated with Myritol and surfactant 
mixture(Smix) of D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) and 
either Tween 20 or Tween 80 at various oil/Smix ratios and water contents. The 
release rate from both groups obviously increased with increasing stirring rate. 
SMEDDS consisting of Myritol 318 and TPGS combined with Tween 80 at 4:1 was 
able to enhance the oral bioavailability of FFB. Tween 80 was better than Tween 20 
in forming smaller particles, which enhanced the invivo absorption rate by faster the 
release rate and complete release were observed. 
Peng Liu et al., 2011, studied, nanosizing techniques were important tools for 
improving the bioavailability of water insoluble drugs. Here, a rapid wet milling 
method was employed to prepare nanosuspension. Photo correlation spectroscopy 
(PCS) results showed that the finest nanosuspension were obtained when 80wt% (to 
drug amount), pluronic F68 used as the stabilizer for indomethacin and 60wt% 
pluronic F127 for itrconazole. The morphology nanoparticles were observed by 
transmission electron microscopy (TEM), crystalline state of the drug before and after 
milling was confirmed using differential scanning calorimetry (DSC). The physical 
and chemical stabilities of the nanosuspension after storage for 2months at room 
temperature and 4
0
C were investigated using PCS,TEM,and HPLC. There was, no 
obvious changes in particle size and morphology. And, there was no chemical 
degradation of the drug ingredients were seen. 
Peng Quan et al., 2011, developed solid formulation containing Nitrendipine 
nanocrystal for oral delivery. Nitrendipine nanocrystals were prepared by using a 
tandem precipitation homogenization process. The optimal process was follows firstly 
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nitrendipine/acetone solution(100mg/ml)was added to a polyvinyl alcohol solution 
(1mg/ml) at 10
o
c, then the presuspension was homogenized for 20 cycles at 1000bar. 
The invitro dissolution rate of the nanocrystal was significantly increased and 
compared with the physical mixture and commercial tablets. The Cmax of the 
nanocrystal was approximately 15 folds and 10 folds greater than that of physical 
mixture and commercial tablet, respectively. And the AUC0→24 of the nanocrystals 
was approximately 41 folds and 10 folds greater than that of physical mixture and 
commercial tablet, respectively. The spray drying method was found to be suitable for 
conversion of the nanocrystal into solid form. 
Huabing Chen et al., 2010, studied, poor water solubility of many drugs and drug 
candidates remains a major obstacle to their development and clinical application. 
Several nanonization techniques that seek to overcome these limitations for drug 
solubilization were presented. The nanoprecipitation method involves the formation 
of crystalline or semi crystalline drug nanoparticles by nucleation and the growth of 
drug crystal. Recent progress in the nanoprecitation techniques has centered on efforts 
to improve the production efficiency of high quality drug nanoparticles. 
Suman katteboinaa et al., 2009, carried out the automation of the drug discovery 
process by technologies such as high throughout screening, combinatorial chemistry 
and computer aided drug design is leading to a vast number of drugs, candidates 
possessing a very good efficacy. Unfortunately, many of these drugs are exhibiting 
poor aqueous solubility. The use of drug nanocrystal is an universal formulation 
approach to increase the therapeutic performance of these drugs in any route of 
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administration. Drug nanocrystals were crystals with a size in the nanometer range, 
meaning that they are nanoparticles with a crystalline character. 
Levent Oner et al., 2009, studied the major application areas of nanotechnology in 
pharmacy is nanoparticular drug delivery systems. Preparation of drug nanocrystals to 
improve the solubility of poorly water soluble drugs for oral delivery is also one of 
the important applications. Nanocrystal dispersion comprises water, active drug 
substance and a stabilizer. Different techniques can be used to prepare nanocrystal 
formulation of a drug powder such as homogenization, co-precipitation, spray drying 
and milling. Nanocrystals are physically stable due to the presence of stabilizers. The 
advantage of Nanocrystals formulations are enhanced oral bioavailability, improved 
dose proportionality, reduced food effects, suitability for administration by all routes 
and possibility of sterile filtration due to decreased particle size range. This 
technology will be substantially useful for the manufacture of poorly water soluble 
drug products for oral delivery. 
N.Jawahar et al., 2009, prepared PLGA [Poly (DL-lactide/glycolide copolymer)] 
nanoparticals of carvedilol, to improved the bioavailability and  prolonged the 
antihypertensive effect of the drug. Carvedilol encapsulated by nanoprecipitation 
method using PLGA and Pluronic F-68. They may have utility for site specific drug 
delivery since the small size of the particle and its biodistribution properties may 
allow their delivery to target sites. 
Adlin Jino Nesalin. J et al., 2009, formulated Flutamide nanoparticles using chitosan 
polymer by ionic gelation technique. Nanoparticles of different core : coat ratio were 
formulated and analysed for total drug content, loading efficiency, particle size and in 
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vitro drug release studies. The drug loading capacity of nanoparticles containing drug 
: polymer in various ratios of 1:1, 1:2, 1:3, 1:4 and 1:5 were found to be 63.3 ± 0.43, 
66.3 ± 0.58, 68.1 ± 0.38, 75.2 ± 0.52, 71.0 ± 0.46. Thus there was a steady increase in 
the entrapment efficiency on increasing the polymer concentration in the formulation. 
The formulation F4 registered highest entrapment of 75.2%. The particle size 
distribution was found to be 400nm by scanning electron microscopy (SEM) analysis. 
From the drug release studies it was observed that nanoparticles prepared with 
chitosan in the core : coat ratio 1:4 was showed better sustained release for about 
12hours as compared to other formulations. 
Rainer Muller. H et al., 2008, developed nanocrystal technology, drug delivery and 
its clinical application. Transfer of material into the nanodimension changes their 
physical properties which were used in pharmaceutics to develop a new innovative 
formulation principle for poorly soluble drugs; the drug nanocrystals. The industrially 
relevant production technology, pearl milling and high pressure homogenization are 
reviewed . The physics behind the drug nanocrystals and changes of the physical 
properties are discussed. It is clearly ideally suited for drugs with solubility problems. 
Particle size diminution and the resulting increase in particle surface, 
curvature,saturation solubility and consequently the increased dissolution velocity are 
important factors. 
Lei Gao et al., 2008, studied, formulation of poorly soluble drug was general 
intractable problem in pharmaceutical field, especially those compounds poorly 
soluble in both aqueous and organic media. It was difficult to resolve this problem 
using conventional formulation approaches, so many drugs were abandoned early in 
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discovery. Nanocrystals, a new carrier free colloidal drug delivery system with a 
particle size ranging from 100nm to 1000nm. They discussed the special features of 
drug nanocrystal with easily scaled up, which was the pre requisite to the 
development of a delivery system as a market product. 
Rainer H Muller et al., 2007, investigated the feasibility of nanosuspension 
technology by high pressure homogenization to enhance the chemical stability of  
ascorbyl palmitate (AP), followed by lyophilization. Sodium dodecyl sulfate (SDS) 
and Tween 80 were chosen as emulsifying agents to stabilize the develop AP 
nanosuspension. After 3 months of storage at 3 different temperature (4
o
C, 25
o
C and 
40
o
C), the photon correlation spectroscopy (PCS) analysis of AP nanosuspension 
revealed that the mean particle size of these stabilized with SDS significantly 
increased compared to those stabilize with Tween 80. The percentage of AP 
remaining in nanosuspension stabilized with Tween 80 was higher than 90% after 
3months storage at 4
o
C, 25
o
C and 40
o
C. To increase the chemical stability of AP 
nanosuspension. A drug powder was prepared by lyophilization. The effect of the 
presence of cryoprotectant terhalose on the physical stability was evaluated at 
different concentrations. After redispersing the lyophilized product the mean size of 
AP nanosuspensions without terhalose was significantly higher compared with system 
with terhalose. It was found that the mean size of AP nanosuspensions stabilized with 
Tween 80 remained in the nanometer range and the amount of the active determined 
by HPLC, was more than 90% when stored at 3 different temperatures during 3 
months. From the X-Ray diffracto grams, it was shown that AP remained in a 
crystalline state which is physiochemically and thermodynamically more stable than 
AP in an amorphous state. 
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Jonghwi Lee et al., 2006, enhanced the oral and parentral delivery of poorly water 
soluble pharmaceutical ingredients(API’s), reports have been limited on the various 
drying procedures to convert a liquid nanocrystal dispersion into solid dosage forms.   
The solid dosage form should consist of nanocrystals that can be readily reconstitute 
into their original size upon dissolution in water. The freeze drying process of 
nanocrystal dispersion was examined at varying freezing rates. As freezing rate 
decrease, more particle-particle aggregation developed. A critical freezing rate, the 
dried nanocrystal can not be re-dispersed. Freeze drying at a freezing rate near the 
critical value produces dry powders of bimodal particle size distribution after re-
dispersion. The study suggests that freezing rate was an important parameter in 
preparing solid dosage forms from nanocrystals dispersion. 
Rainer H Muller et al., 2005, developed drug nanocrystal by bottom up technique 
(precipitation) was briefly described, main fours were given on particle diminution by 
high pressure homogenization. There was also a combination process of precipitation 
followed by a second high energy step eg homogenization. Finally  suspension of 
drug nanocrystals in a liquid, were prepared and called as nanosuspension. The effect 
of production parameters (power density, number of homogenization cycles) on 
crystal size. As an important point the transfer of the liquid nanosuspension to patient 
convenient oral dosage forms such as tablets and/or capsules were described. 
Amighi K et al., 2005, prepared nifedipine nanoparticles  using high pressure 
homogenization. Nanoparticals were characterized in terms of size, morphology and 
redispersion characteristics following water removal. Saturation solubility and 
dissolution characteristics were investigated and compared to the un-milled 
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commercial NIF to verify the theoretical hypothesis on the benefit of increased 
surface area. Crystalline state evaluation before and following particle size reduction 
was also conducted through differential scanning calorimeter (DSC) and Powder X-
Ray diffraction (PXRD). Through this study it has been shown that initial crystalline 
state is maintained following particle size reduction and that the dissolution 
characteristics of Nifedipine nanoparticles were significantly increased in regards to 
the commercial product. This approach should have a general applicability to many 
poorly water soluble drug entities. 
Jonghwi Lee et al., 2005, reported the role of polymeric stabilizers for drug 
nanocrystal dispersions. Also successfully developed the wet comminution process 
for drug nanocrystals in the presence of polymeric stabilizers. The selection of proper 
stabilizer for the drug was chosen by studying the nature of interaction between 
polymeric stabilizers and drug by analyzing the steady state particle sizes of seven 
drugs obtain by wet comminution. The surface energy of drugs and polymers were 
measured by contact angle measurement. The stabilization ability of polymers and the 
subsequent steady state particle size of drug nanocrystal depend on various 
parameters including surface energy and specific interactions. 
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CHAPTER-IV 
AIM OF THE WORK 
During the last two decades, many modern technologies such as high 
throughput screening, combinatorial chemistry, and computer-aided drug design in 
the pharmaceutical research and development area is leading to a vast number of drug 
candidates possessing a very good efficacy. Unfortunately many of these drug 
candidates are exhibiting poor aqueous solubility. Although some approaches are 
available for enhancing the dissolution of poorly soluble drugs, but has certain 
drawbacks like low drug loading and large dose. However, a new solution to poorly 
water soluble drugs candidates are now available, that is, nanonisation, and it leads to 
much more soluble, more biologically available and safer dosage form of poorly 
soluble and poorly available drugs. 
 Ramipril is a prodrug, and is converted to the active metabolite Ramiprilat, by 
liver esterase enzyme. It is an angiotensin converting enzyme (ACE) inhibitor, used to 
treat hypertension and congestive heart failure. Ramipril is chemically (2S,3aS,6aS)-
1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2yl]amino}propanoyl 
octahydrocyclopenta[b]pyrrole-2-carboxylic acid. Ramipril lowers the production of 
angiotensin II from angiotensin I by inhibiting angiotensin converting enzyme (ACE). 
Therefore, relaxing arterial muscles, while at the same time enlarging the arteries, 
allowing the heart to pump blood, more easily into large passageways. 
 The absolute oral bioavailability of Ramipril following oral administration is 
28%-30%. It is soluble in methyl alcohol and sparingly soluble in water. (Harish 
Chander et al., 2011) 
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 Drug nanocrystals are pure solid drug particles with a mean diameter below 
1000nm. According to the Noyes-Whitey equation, a decrease in particle size will 
lead to an increase in effective surface area in the diffusion layer, which, in turn, 
increase the drug dissolution rate. Nanocrystal is also a registered trademark of Elan 
Pharma International Ltd (Ireland). Drug nanocrstals are one of the most important 
strategies to enhance the oral bioavailability of sparingly water soluble drugs. Drugs 
nanocrystals can be used for chemical stabilization of chemically labile drugs. The 
increased stability can be explained by a shield effect of surfactants and the drug 
protection by a monolayer made of degraded drug molecules which reduce the 
accessibility for destructive agents. 
 The present study is carried out to develop nanocrystal of Ramipril, in order to 
enhance solubility and bioavailability, by decreasing the particle size of the drug. 
Drugs nanocrystals are prepared by emulsion solvent diffusion method. Solubility and 
dissolution profile of obtained nanocrystals are compared with pure drug. 
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CHAPTER-V 
PLAN OF WORK 
1. STANDARD CURVES FOR RAMIPRIL 
a) Preparation of calibration medium 
b) Estimation of absorption maximum (λmax) 
c) Preparation of standard curves 
  
2. PREFORMULATION (COMPATABILITY) STUDIES 
a) Infrared (IR) spectroscopic studies 
 
3. FORMULATION OF RAMIPRIL NANOCRYSTALS 
The nanocrystals are prepared by emulsion solvent diffusion method. The 
preparation process involves following steps. 
a) Formulation of Ramipril nanosuspensions 
b) Lyophilization of nanosuspensions to obtain the nanocrystals 
 
4. CHARACTERIZATION OF RAMIPRIL NANOCRYSTALS 
a) Determination of drug content 
b) In vitro dissolution studies 
c) Determination of Particle size and Zeta potential 
d) Solubility studies 
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5. SELECTION AND EVALUATION OF BEST FORMULATION 
 The best formulation is selected depending on the results obtained from 
particle size, in-vitro drug release studies and solubility studies 
 
a) Infrared (IR) spectroscopic studies  
b) Scanning Electron Microscopy (SEM) 
c) X-ray Powder Diffraction (XRPD) analysis. 
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CHAPTER-VI 
MATERIALS AND EQUIPMENTS 
MATERIALS USED: 
 
 
MATERIALS NAME 
 
 
SUPPLIERS 
 
Ramipril 
 
Gift samples from Dr.Reddy’s Laboratories, 
Hydrabad. 
 
Hydroxy Propyl Methyl 
Cellulose (HPMC) K15M 
 
Gift samples from Steril-gene Life science (P) 
Ltd, Pondicherry. 
 
Poly vinyl pyrrolidone (PVP 
K30) 
 
Gift sample from Shasun Pharmaceuticals, 
Pondicherry. 
 
β Cyclodextrin (BCD) 
 
Nice chemicals, Cochin. 
 
Sodium Lauryl Sulphate (SLS) 
 
Rankem fertilizers and chemicals (P) Ltd, New 
Delhi. 
 
Poly Ethylene Glycol (PEG) 
6000 
 
High Purity Laboratory Chemicals (P) Ltd, 
Mumbai. 
 
Methanol 
 
Universal Scientific Appliances, Madurai. 
 
Potassium dihydrogen Phosphate 
 
High Purity Laboratory Chemicals (P) Ltd, 
Mumbai. 
 
Sodium Hydroxide 
 
High Purity Laboratory Chemicals (P) Ltd, 
Mumbai. 
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EQUIPMENTS USED: 
 
EQUIPMENTS NAME MANUFACTURER’S 
Electronic weighing balance A & D Company, Japan. 
UV-Visible spectrophotometer Shimadzu Corporation, Japan. 
Infrared spectroscopy Spectrum RX-1, Perkin Elmer, German. 
Homogenizer M.S.E. Ltd., England 
Refrigerator Kelvinator, India. 
Scanning electron microscope Hitachi X650, Tokyo, Japan. 
Particle size analyzer Nano ZS 90, Malvern Instruments Ltd.,UK 
Freeze dryer Lyodel-Delvac Pumps Pvt. Ltd, USA. 
Mechanical shaker Secor, India. 
Environmental chamber Inlab equipments Pvt. Ltd., Madras. 
Dissolution apparatus Labindia – Disso 2000, India. 
Ultra Sonicator Vibronic
’
s Ultrasonic processor, India. 
X-ray diffractometer Digaku XRD-462, Japan. 
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CHAPTER-VII 
DRUG PROFILE 
DRUG NAME : RAMIPRIL 
SYNONYM : HOE-498; Ramiprilum 
STRUCTURAL FORMULA : 
 
 
CHEMICAL FORMULA : C23 H32 N2O5 
CHEMICAL NAME: 
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-
2yl]amino}propanoyl octahydrocyclopenta[b]pyrrole-2-carboxylic acid 
DESCRIPTION: 
Physical state     :  white crystalline powder. 
Solubility                              : Ramipril is freely soluble in methanol 
and sparingly soluble in water 
Molecular weight   : 416.5 g/mol 
pKa      :  5.2 
log P              :  1.47 
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Refractivity             : 111.19   
Melting point            :  109° C 
Polarizability             : 44.78 
MECHANISM OF ACTION: 
Ramipril is a prodrug, and is converted to the active metabolite Ramiprilat, by 
liver esterase enzyme. It is an angiotensin converting enzyme (ACE) inhibitor, used to 
treat hypertension and congestive heart failure.  Ramipril lowers the production of 
angiotensin II from angiotensin I by inhibiting angiotensin converting enzyme (ACE). 
Therefore, relaxing arterial muscles, while at the same time enlarging the arteries, 
allowing the heart to pump blood, more easily into large passageways. Ramipril also 
causes an increase in plasma rennin activity likely due to loss of feedback inhibition 
mediated by angiotensin II on the release of rennin and stimulation of releax 
mechanisms via baroreceptors. 
PHARMACOKINETICS: 
Absorption: 
 The absolute oral bioavailability of Ramipril following oral administration is 
28%-30%. The extent of absorption is at least 50-60%. Food decreases the rate of 
absorption from the GI tract without affecting the extent of absorption, when oral 
administration is compare to intravenous administration. 
Volume of distribution: 
 Mean volume of distribution at steady-state of Ramipril is approximately 90 
liters. 
Protein binding: 
The plasma protein binding of racemic Paliperidone is 73%. 
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Metabolism: 
Ramipril is metabolized in the liver to the active drug metabolite of Ramiprilat 
by hydrolysis via liver esterase enzymes. Other metabolites, diketopiperazine ester, 
the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat, are 
inactive. 
Route of elimination: 
Ramipril is almost completely metabolised and the metabolites are excreted 
mainly via the kidneys (60%), and feces (40%).  
INDICATIONS AND USAGE: 
  Mild to moderate hypertension. 
  Cardiac failure following myocardial infarction. 
  To reduce proteinuria and the decline in glomerular filtration rate in 
patients with diabetic nephropathy and hypertension. 
  To reduce the risk of myocardial infarction, stroke or cardiovascular 
death and to reduce the need for revascularization procedures in patients with an 
increased cardiovascular risk [such as manifest coronary heart disease (with or 
without a history of myocardial infarction), a history of stroke or a history of 
peripheral vascular disease].. 
  To reduce the risk of myocardial infarction stroke or cardiovascular 
death in diabetic patients. 
DOSING: 
For hypertension: The dose range is 2.5 mg to 10 mg as a single daily dose. The 
antihypertensive effect is evident within one to two hours after intake of the medicine, 
peak effect occurs three to six hours after intake and has been shown to be maintained 
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for at least 24 hours at recommended doses. A maximum dose of 10 mg should not be 
exceeded. 
For Post-Myocardial Infarction: The recommended dosage is 2.5 mg twice daily for 
two days. If well tolerated increase the dose to ramipril 5 mg twice daily. If patients 
are unable to tolerate 2.5 mg initially, 1.25 mg twice daily may be given initially and 
later increased to 2.5 mg twice daily. 
For Non-diabetic and diabetic nephropathy: The recommended initial dose is 
1.25 mg once daily. Depending on how the patient tolerates the medicine, the dose 
should be increased to doubled at intervals of 2 to 3 weeks. Maximum permitted daily 
dose is 10 mg. 
To reduce the risk of myocardial infarction, stroke or cardiovascular death: The 
recommended initial dose is 2.5 mg once daily. Depending on the tolerability, the 
dose is gradually increased to doubling, after one week of treatment. Three weeks 
later, it should be doubled again to the usual maintenance dose of 10 mg once daily. 
Dosage Adjustment in Renal Impairment: Drugs are not recommended for use in 
dialysis patients. 
DOSAGE FORMS: 
Capsule - Oral 1.25mg 
Capsule – Oral 2.5mg 
Capsule – Oral 5mg 
Capsule – Oral 10mg 
Capsule – Oral 15mg 
Tablet – Oral 1.25mg 
Tablet – Oral 2.5mg 
Tablet – Oral 5mg 
Tablet – Oral 10mg 
Tablet – Oral 15mg 
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ADVERSE REACTIONS: 
Haematological:  
Less frequent: Decrease in white blood cell count, haemoglobin and 
haemocrit, bone marrow depression, anaemia, thrombocytopenia, agranulocytosis, 
haemolytic anaemia. 
Cardiovascular: 
 Less frequent: Orthostatic effects including hypotension, myocardial 
infarction, cerebrovascular accident, palpitations and tachycardia. 
Neurological: 
 More frequent: Dizziness, headache, fatigue. 
 Less frequent: Mood alterations, mental confusion, paraesthesia, vertigo, sleep 
disturbances. 
Endocrine/Metabolic:  
 Less frequent: Hyperkalaemia, hyponatraemia, increases in blood urea, 
increases in serum creatinine. 
Gastro-intestinal: 
 More frequent: Diarrhoea, nausea. 
 Less frequent: Abdominal pain, indigestion, dry mouth, pancreatitis, vomiting 
and taste disturbances. 
Kidney/Genito-urinary: 
 Less frequent: Uraemia, oligouria, anuria, renal dysfunction, acute renal 
failure, impotence. 
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Liver/Hepatic: 
 Less frequent: Hepatitis (hepatocellular or cholestatic) jaundice, increase in 
liver enzymes, increase in serum bilirubin. 
Musculoskeletal: 
 Less frequent: Asthenia. 
Respiratory: 
 More frequent: Cough. 
 Less frequent: Bronchospasm, rhinitis, sinusitis. 
Skin: 
 Less frequent: Rash, urticaria, diaphoresis, alopecia, pruritus psoriasis, severe 
skin disorders including pemphigus, toxic epidermal necrolysis, Stevens-Johnson 
Syndrome and erythema multiforme. 
Others: 
 Less frequent: angioedema reactions like Angioedema of the face, which may 
be fatal, extremities, lips, tongue, glottis and/or larynx and intestinal angioedema. A 
symptom complex has been reported which may include fever, vasculitis, myalgia, 
arthritis/arthralgia, positive antinuclear antibodies (ANA), elevated erythrocyte 
sedimentation rate, eosinophilia and leucocytosis. 
OVERDOSAGE: 
While experience with Ramipril overdose is Severe hypotension, electrolyte 
disturbances and renal failure. 
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CONTRAINDICATIONS 
Sensitivity to any of the components of ramipril, patients with a history of 
angioedema related to previous ACE-inhibitor therapy or angiotensin receptor 
blocker. Hereditary or idiopathic angioedema. Aortic stenosis. Hypertrophic 
obstructive cardiomyopathy. Severe renal function impairment (creatinine clearance 
below 30 mL/min). Renal artery stenosis in patients with a single kidney. 
Concomitant therapy with potassium sparing diuretics such as spironolactone, 
triamtrene, amiloride. Porphyria. 
DRUG INTERACTIONS:  
 Co-administration with Amiloride, increased risk of hyperkalemia. 
 Co-administration with Azilsartan medoxomil, dual blockade of renin-
angiotensin system. Increases risks of hypotension, hyperkalemia, renal 
impairment. 
 Co-administration with Drospirenone, increased risk of hyperkalemia. 
 Co-administration with Icatibant, may attenuate the antihypertensive effect of 
ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant 
therapy closely. 
 Concomitant therapy with Ramipril may increase the blood-glucose-lowering 
effect of insulin lispro and thus the chance of hypoglycemia should be 
monitored closely. 
 Increases  the serum levels of lithium, when administered with Ramipril. 
 Co-administration with Spironolactone, potassium, Triamterene, increased risk 
of hyperkalemia. 
 Tizanidine increases the risk of hypotension with Ramipril. 
 Co-administration with Tobramycin, increased risk of nephrotoxicity. 
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BRAND NAME: 
 Cardiopril (Dr.Reddy’s)., 
 Cardace (Sanofi Aventis)., 
 Hopace (Micro Cardicare)., 
 Ramace (Astra Zeneca)., 
 Ramipres (Cipla)., 
 Ramipro (Emcure)., 
 Ramiril (Micro labs)., 
 Ramistar (Lupin Pinnacle)., 
 Topril (Torrent Delta)., 
 
(Drugbank.com., Clarke’s Analysis of Drugs and Poisons 3rd Edition) 
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CHAPTER-VIII 
EXCIPIENTS PROFILE 
HYDROXY PROPYL METHYL CELLULOSE 
SYNONYM: 
 Hypromellose. 
 Methocel 
STRUCTURE: 
(Hand book of Pharmaceutical Excipients. Pharmaceutical Press, London. 5
th
edtition) 
 
 where R is H, CH3, or CH3CH(OH)CH2 
EMPIRICAL FORMULA: 
 It is a partly O-methylated and O-(2-hydroxypropylated) cellulose.  It is 
available in several grades that vary in viscosity and extent of substitution. 
MOLECULAR WEIGHT: 
 10 000–1 500 000 Dalton 
DESCRIPTION: 
 Colour: white or creamy-white fibrous or granular powder. 
 Odour: odourless. 
 Taste: Tasteless. 
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 Solubility: Soluble in cold water, forming a viscous colloidal solution; 
practically insoluble in hot water, chloroform, ethanol (95%), and ether, but 
soluble in mixtures of ethanol and dichloromethane, mixtures of methanol and 
dichloromethane, and mixtures of water and alcohol. Certain grades of 
hypromellose are soluble in aqueous acetone solutions, mixtures of 
dichloromethane and propan-2-ol, and other organic solvents.  Some grades 
are swellable in ethanol. 
 Melting point:  Browns at 190–2008C; chars at 225–2308C 
METHOD OF MANUFACTURE: 
 A purified form of cellulose, obtained from cotton linters or wood pulp, is 
reacted with sodium hydroxide solution to produce a swollen alkali cellulose that is 
chemically more reactive thanuntreated cellulose.  The alkali cellulose is then treated 
with chloromethane and propylene oxide to produce methyl hydroxypropyl ethers of 
cellulose.  The fibrous reaction product is then purified and ground to a fine, uniform 
powder or granules.  Hypromellose can then be exposed to anhydrous hydrogen 
chloride to induce depolymerization, thus producing low viscosity grades. 
Typical viscosity values for 2 % (w/v) aqueous solutions of different viscosity 
grades of hpmc at 20°c: 
Methocel K100 Premium LVEP : 100 
Methocel K4M Premium  : 4000 
Methocel K15M Premium  : 15000 
Methocel K100M Premium  : 100 000 
Methocel E4M Premium  : 4000 
Methocel F50 Premium  : 50 
Methocel E10M Premium CR : 10 000 
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Methocel E3 Premium LV  : 3 
Methocel E5 Premium LV  : 5 
Methocel E6 Premium LV   : 6 
Methocel E15 Premium LV  : 15 
Methocel E50 Premium LV  : 50 
Metolose 60SH   : 50, 4000, 10 000 
Metolose 65SH   : 50, 400, 1500, 4000 
Metolose 90SH   : 100, 400, 4000, 15 000  
STORAGE CONDITION: 
 It should be stored in a well-closed container, in a cool, dry place. 
HANDLING PRECAUTION: 
 Hypromellose dust may be irritant to the eyes and eye protection is 
recommended.  
 Excessive dust generation should be avoided to minimize the risks of 
explosion.  Hypromellose is combustible. 
(Hand book of Pharmaceutical Excipients by Raymond C. Rowe et.al., 2009) 
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PVP K 30  
SYNONYM: 
 Kollidon  
 Plasdone 
 poly[1-(2-oxo-1-pyrrolidinyl)ethylene]   
 Polyvidone;Polyvinylpyrrolidone  
 PVP; 1-vinyl-2-pyrrolidinone polymer. 
STRUCTURE: 
 
CHEMICAL NAME: 
1-Ethenyl-2-pyrrolidinone homopolymer 
EMPIRICAL FORMULA: 
(C6H9NO)n               2500–3 000 000 
                     The USP 28 describes povidone as a synthetic polymer consisting 
essentially of linear 1-vinyl-2-pyrrolidinone groups, the differing degree of 
polymerization of which results in polymers of various molecular weights. It is 
characterized by its viscosity in aqueous solution, relative to that of water, expressed 
as a K-value, in the range 10–120. 
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The K-value is calculated using Fikentscher’s equation: 
   75k2 
Log z = c _____ 
  1+1.5kc 
where z is the relative viscosity of the solution of concentration c (in % w/v), 
and k is the K-value ×10
-3
 
MOLECULAR WEIGHT: 50000 
FUNCTIONAL CATEGORY: 
Disintegrant; dissolution aid; suspending agent; tablet binder 
DESCRIPTION: 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. 
PROPERTIES: 
Physical state  :      white powder 
Solubility                     :  freely soluble in acids, chloroform, ethanol (95%),                       
ketones,    methanol, and water; practically 
insoluble in ether, hydrocarbons, and mineral oil. 
HANDLING PRECAUTIONS: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection is recommended 
STABILITY AND STORAGE CONDITIONS: 
Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, it should be 
stored in an airtight container in a cool, dry place. 
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SAFETY: 
Povidone is widely used as an excipient, particularly in oral tablets and 
solutions. When consumed orally, povidone may be regarded as essentially nontoxic 
since it is not absorbed from the gastrointestinal tract or mucous membranes. 
Additionally it has no irritant effect on the skin and causes no sensitization. 
 
(Handbook ofPharmaceutical excipients- 5
th
 edition, 641-643). 
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BETACYCLODEXTRINS 
 SYNONYMS: 
 b-Cyclodextrin beta-cycloamylose 
 Beta-dextrin 
 Betadexum 
EMPIRICAL FORMULA : C42H7035  
MOLECULAR WEIGHT :  1135 
STRUCTURAL FORMULA: 
 
 
FUNCTIONAL CATEGORY: 
Solubilizing agent; stabilizing agent. 
PHARMACOPEIAL SPECIFICATIONS: 
SOLUBILITY :  
Soluble 1 in 200 parts of propylene glycol, 1in50 of water at 208C, 1 in 20 at 
508C; practically insoluble in acetone, ethanol (95%), and methylene chloride. 
SPECIFIC ROTATION   :  D25= þ162.08; 
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SURFACE TENSION (AT 258C) n:   71 mN/m (71 dynes/cm); 
STABILITY AND STORAGE CONDITIONS: 
β-Cyclodextrin is stable in the solid state if protected from high humidity. β-
Cyclodextrins should be stored in a tightly sealed container, in a cool, dry place. 
METHOD OF MANUFACTURE: 
Betacyclodextrin is produced by the action of the enzyme cyclodextrin 
glucosyltransferase upon starch or a starch hydrolysate. An organic solvent is used to 
direct the reaction that produces betacyclodextrin, and to prevent the growth of 
microorganisms during the enzymatic reaction. The insoluble complex of 
betacyclodextrin and organic solvent is separated from the non cyclic starch, and the 
organic solvent is removed in vacuum so that less than 1 ppm of solvent remains in 
the betacyclodextrin. The betacyclodextrin is then carbon treated and crystallized 
from water, dried, and collected. 
SAFETY: 
 nontoxic and nonirritant 
 cyclodextrins are  approved for use in food products and orally 
administered     pharmaceuticals in a number of countries. 
 Cyclodextrins are not irritant to the skin and eyes, or upon inhalation.  
 There is also no evidence to suggest that cyclodextrins are mutagenic 
or teratogenic. 
HANDLING PRECAUTIONS: 
should be handled in a well-ventilated environment. 
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SODIUM LAURYL SULFATE 
SYNONYMS: 
 Dodecyl sodium sulfate. 
 Elfan 240. 
 Texapon K12P.   
 Sodium dodecyl sulfate.   
 Sodium monododecyl sulfate. 
CHEMICAL NAME: 
Sulfuric acid monododecyl ester sodium salt. 
CHEMICAL STRUCTURE: 
 
 
EMPIRICAL FORMULA: C12H25NaO4S 
MOLECULAR WEIGHT: 288.38 
HLB VALUE: ≈ 40 
FUNCTIONAL CATEGORY: 
Anionic surfactant; detergent; emulsifying agent; skin penetrant; tablet and 
capsule lubricant; wetting agent. 
APPLICATION IN PHARMACEUTICAL FORMULATION AND 
TECHNOLOGY: 
Sodium lauryl sulfate is an anionic surfactant employed in a wide range of non 
parentral pharmaceutical formulations and cosmetics. 
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Use Concentration (%) 
Anionic emulsifiers, forms self emulsifying bases 
with fatty alcohols 
0.5–2.5 
Detergent in medicated shampoos ≈10 
Skin cleanser in topical applications 1 
Solubilizer in concentrations greater than critical 
micelle concentration 
>0.0025 
Tablet lubricant 1.0–2.0 
Wetting agent in dentrifices 1.0–2.0 
 
 It is a detergent and wetting agent effective in both alkaline and acidic 
conditions. 
 In recent years it has found application in analytical electrophoretic 
techniques;SDS (sodium dodecyl sulfate) polyacrylamide gel electrophoresisis 
one of the more widely used techniques for the analysis of proteins. 
 The sodium lauryl sulfate has been used to enhance the selectivity of micellar 
electrokinetic chromatography (MEKC). 
DESCRIPTION: 
           SLS consists of white or cream to pale yellow- colored crystals, flakes, or 
powder having a smooth feel, a soapy. Bitter taste and a faint odour of fatty 
substances. 
MELTING POINT: 
204-207°c (for pure substance) 
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SOLUBILITY: 
Freely soluble in water, giving an opalescent solution; practically insoluble in 
chloroform and ether. 
STABILITY AND STORAGE CONDITION: 
Sodium lauryl sulfate is stable under normal storage conditions. However, in 
solution, under extreme conditions i.e. PH 2.5 or below, it undergoes hydrolysis to 
lauryl alcohol and sodium bisulfate. 
            The bulk material should be stored in a well closed container away from 
strong oxidizing agents in a cool, dry place. 
INCOMPATIBILITIES: 
Sodium lauryl sulfate reacts with cationic surfactants, causing loss of activity 
even in concentrations too low to cause precipitation. Unlike soaps, it is compatible 
with dilute acids and calcium and magnesium ions. Solutions of sodium lauryl sulfate 
(PH 9.5-10.0) are mildly corrosive to mild steel, copper, brass, bronze and aluminium. 
Sodium lauryl sulfate is also in compatible with some alkaloidal salts and precipitates 
with lead and potassium. 
HANDLING PRECAUTIONS: 
 Inhalation and contact with the skin and eyes should be avoided; eye 
protection gloves, and other protective clothing, depending on the 
circumstances, are recommended. 
 Adequate ventilation should be provided or a dust respirator should be worn. 
Prolonged or repeated exposure should be avoided.  
 Sodium lauryl sulfate emits toxic fumes on combustion.  
(Hand book of Pharmaceutical excipients by Raymond C Rowe -5
th
 edition, 
1811- 1816). 
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PEG-6000 
SYNONYM: 
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; Pluriol E; 
polyoxyethylene      glycol. 
STRUCTURE: 
 
CHEMICAL NAME: 
a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) 
EMPIRICAL FORMULA: 
 HOCH2(CH2OCH2)mCH2OH  
                 where m represents the average number of oxyethylene groups. 
Alternatively, the general formula H(OCH2CH2)nOH may be used to represent 
polyethylene glycol, where n is a number m in the previous formula +1. 
MOLECULAR WEIGHT  :  6000 
FUNCTIONAL CATEGORY: 
Ointment base; plasticizer; solvent; suppository base; tablet and capsule 
lubricant. 
DESCRIPTION: 
The USPNF 23 describes polyethylene glycol as being an addition polymer of 
ethylene oxide and water. Polyethylene glycol grades 200–600 are liquids; grades 
1000 and above are solids at ambient temperatures. 
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                   Solid grades (PEG>1000) are white or off-white in color, and range in 
consistency from pastes to waxy flakes. They have a faint, sweet odor. Grades of PEG 
6000 and above are available as free-flowing milled powders. 
PROPERTIES: 
Physical state  : white flakes 
Solubility in water : soluble in water 
Solvent solubility : soluble in methanol, ethanol(95%). 
HANDLING PRECAUTION: 
Observe normal precautions appropriate to the circumstances  and quantity of   
material handled. Eye protection is recommended. 
STABILITY AND STORAGE CONDITIONS: 
Polyethylene glycols are chemically stable in air and in solution, Polyethylene 
glycols should be stored in well-closed containers in a cool, dry place. 
SAFETY: 
Polyethylene glycols are widely used in a variety of pharmaceutical 
formulations. Generally, they are regarded as nontoxic and nonirritant materials. 
Adverse reactions to polyethylene glycols have been reported, the greatest toxicity 
being with glycols of low molecular weight. However, the toxicity of glycols is 
relatively low. 
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CHAPTER-IX 
EXPERIMENTAL PROTOCOL 
1. STANDARD CURVES FOR RAMIPRIL: 
a) Preparation of calibration medium (Indian Pharmacopoeia 2010): 
Phosphate Buffer pH 6.8: 
 A known volume (50ml) of 0.2M potassium dihydrogen phosphate is placed 
in a 200ml volumetric flask. 22.4ml of 0.2M sodium hydroxide is added and makeup 
to the volume with distilled water. 
• 0.2 M potassium dihydrogen phosphate: 
 A known quantity (27.218 g) of potassium dihydrogen phosphate is dissolved 
and diluted to 1000ml with water. 
• 0.2 M sodium hydroxide: 
A known quantity (8 g) of sodium hydroxide is dissolved and makeup to 
1000ml with water. 
b) Estimation of absorption maximum (λmax): 
A known weight (10 mg) of drug (Ramipril) is  dissolved in sufficient amount 
of methanol in 100ml volumetric flask and make upto 100ml with phosphate buffer 
pH (6.8) to prepare a primary stock solution (100µg/ml). The stock solution is further 
diluted using a phosphate buffer  pH (6.8) solution to 10µg/ ml  concentration. The 
resultant solution is scanned in the range of (200- 400nm) by UV Spectrophotometer  
(UV-1700 Shimadzu corporation, Japan) to get absorption maximum (λ max).  
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 c) Preparation of standard curves: 
From the above prepared stock solution, (5 to 25µg/ml) concentration  
solutions are prepared using  the phosphate buffer pH (6.8) solution. The absorbance 
of these solutions are measured  at λ max by UV- spectrophotometer (UV-1700 
Shimadzu corporation, Japan). A standard curve is plotted using concentration on X-
axis and the absorbance obtained on Y-axis. (Harish Chander., et al, 2011) 
2. PREFORMULATION (COMPATABILITY) STUDIES: 
preformulation studies are carried out by Infrared spectrophotometer in order 
to evaluate the drug and stabilizer interaction. 
a) Infrared (IR) spectroscopic studies: 
Infrared (IR) spectrum of the drug, stabilizers, and its physical mixtures are 
obtained by using IR spectrophotometer (Spectrum RX-1 Perkin Elmer, German). The 
pellets are prepared on KBr-press under hydraulic pressure of 150kg / cm
2
; the spectra 
is scanned over the wave number range of 4000 to 400 cm
-1
 at the ambient 
temperature (Sinco.C et al., 2011). 
3. FORMULATION OF RAMIPRIL NANOCRYSTALS: 
The nanocrystals are prepared by emulsion solvent diffusion method. The 
preparation process involves following steps (Phanchaxari M Dandagi et al., 2011). 
a) Formulation of Ramipril nanosuspensions; 
b) Lyophilization of nanosuspensions to obtain the nanocrystals. 
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a) Formulation of Ramipril nanosuspensions: 
i)Preparation of drug solution: 
Accurately weighed sample (100 mg) of drug is added to methanol (10 ml) to 
prepare the drug solution. 
ii) Addition of drug solution to aqueous solution containing stabilizers: 
The above prepared drug solution is to be added into required quantity (10ml) 
of water containing  stabilizers (HPMC K15M, PVP K30, β-CYCLODEXTRIN, 
SODIUM LAURYL SULPHATE, and PEG 6000) with continuous stirring on 
homogenizer at 1000 rpm for 2 hours 
iii) Removal of solvent: 
The organic solvent is removed by continuous stirring for 3-4 hours at 500 
rpm (Phanchaxari M Dandagi et al., 2011). 
b) Lyophilization of nanosuspensions to obtain the nanocrystals: 
Ramipril nanosuspensions are lyophilized by using freeze dryer (Lyodel-
Delvac Pumps Pvt. Ltd, USA) to enhance the chemical stability of nanocrystals. The 
freshly prepared nanosuspensions are lyophilized with cryoprotective agent 
(mannitol). Briefly, Ramipril nanosuspensions are rapidly cooled down to -50
0
C for 2 
hours followed by primary drying at 1.03 mbar and secondary drying at 0.001 mbar 
(Rainer Muller. H et al., 2008). 
4. CHARACTERIZATION OF RAMIPRIL NANOCRYSTALS: 
All the formulations are evaluated for its particle size, zeta potential, drug 
content, and in vitro drug release studies 
. 
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a) Determination of drug content: 
  Sample containing 10 mg equivalent of Ramipril nanocrystals are weighed and 
dissolved in methanol, and the volume is made upto 100ml with phosphate buffer 
pH(6.8). From the above solution 10 ml is pipetted out and made upto 100 ml with 
phosphate buffer pH(6.8). The absorbance of resulting solution is determined at λmax 
(277 nm) using UV Spectrophotometer (UV-1700 Shimadzu corporation, Japan) and 
the drug content is estimated (Phanchaxari M Dandagi et al., 2010). 
b)  In vitro dissolution studies: 
USP dissolution apparatus Type II (paddle method) at rotation speed of 100 
rpm is used for in vitro testing of drug dissolution of all nanocrystal formulations. For 
each batch, sample of 10 mg equivalent Ramipril nanocrystals containing in capsules 
are taken and subjected to dissolution studies with 900 ml of  phosphate buffer 
pH(6.8)  as dissolution medium. Bath temperature is maintained at 37±0.5°C 
throughout study. 
  A sample (5 ml) of the solution is withdrawn from the dissolution apparatus 
at predetermined time intravels of 5, 10, 20, 30, 40, 60, 90, and 120mins. The samples 
are replaced with fresh dissolution medium. Absorbance values of sample solutions 
are measured at λmax ( 277 nm) in UV Spectrophotometer (UV-1700 Shimadzu 
corporation, Japan). The cumulative percentage drug  release is calculated (Doaa 
Ahmed El-Setouhy et al., 2011). 
c) Determination of Particle size and Zeta potential: 
 The mean particle size (z-average), and zeta potential of Ramipril nanocrystal 
formulations  are determined by dynamic light scattering technique using a zeta size 
analyzer (Nano ZS 90, Malvern Instruments Ltd., UK). The freeze dried powders are 
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redispersed with water to obtain a proper scattering intensity before measurement 
(Dianrui Zhang et al., 2012). 
d) Solubility studies: 
Solubility of Ramipril nanocrystal formulations are studied  in different 
solvents such as distilled water  and phosphate buffer pH(6.8). An excess amount of  
nanocrystal formulation is added in 10 ml of the pertinent solvents. The mixtures are 
stirred in a mechanical shaker for 24 hours. Visual inspection is carefully made to 
ensure there are excess Ramipril solids in the mixture, indicating saturation have been 
reached. The mixtures are then filtered and filtrates are diluted suitably to determine 
the solubility of Ramipril in each solvent (Abdul Hasan Sathali.A., and 
Gopinath.M., 2013). 
5. SELECTION AND EVALUATION OF BEST FORMULATION: 
The best formulation is selected depending on the results obtained from 
particle size, in vitro drug release studies and solubility studies. 
a) Infrared (IR) spectroscopic studies:  
Infrared (IR)   spectrum analysis are carried out for the selected nanocrystal 
formulation  to find out the interactions between the drug and excipients by using IR 
spectrophotometer (Spectrum RX-1 Perkin Elmer, German). The pellets are prepared 
on KBr-press under hydraulic pressure of 150kg / cm
2
; the spectra is scanned over the 
wave number range of 4000 to 400 cm
-1
 at the ambient temperature (Sinco.C et al., 
2011). 
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b) Morphological studies of nanocrystals by using Scanning Electron Microscopy 
(SEM): 
Morphological evaluation of the selected Ramipril nanocrystal formulation is 
carried out in scanning electron microscope (SEM) (Hitachi X650, Tokyo, Japan). All 
samples are examined on a brass stub using carbon double-sided tape. Powder 
samples are glued and mounted on metal sample plates. The samples are gold coated 
(thickness ≈15–20 nm) with a sputter coater (Fison Instruments, UK) using an 
electrical potential of 2.0 kV at 25 mA for 10 min. An excitation voltage of 20 kV 
was used in the experiments (Yuan Gao et al., 2011). 
c) X-ray Powder Diffraction (XRPD) analysis: 
The crystalline state of the samples, including the drug and freeze-dried 
powders are studied in X-ray diffractometer (XRD-462, Digaku, Japan). XRPD is 
carried out in symmetrical reflection mode using Copper line as the source of 
radiation and the wavelength is set at 1.5405A˚.  Standard runs using a 40 kV and 30 
mA in this process. Samples are performed with a scanning rate of 0.1000
◦
/min and 
the scanning range of the 2  from the initial angle 4˚ to the final angle 90˚ (Dianrui 
Zhang et al., 2011). 
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CHAPTER-X 
RESULTS AND DISCUSSION 
1. STANDARD CURVES FOR RAMIPRIL 
a) Preparation of calibration medium 
The calibration medium pH (6.8) were prepared by using  phosphate buffer  as 
per the I.P procedure. 
b) Estimation of absorption maximum (λmax) 
The λ max of ramipril was estimated by scanning the 10μg/ml concentration 
of the drug solution in buffer solution of pH (6.8). It showed the λ max of 277nm 
(Narendra Chary., et al., 2012) in buffer solution of pH (6.8). The results were shown 
in (Figure 10a). 
c) Preparation of standard curves 
The standard curves of ramipril prepared by using phosphate buffer pH(6.8) 
were shown in (Table 1) and (Figure 10b). The linear correlation coefficient was 
found to be 0.9995 for pH (6.8). ramipril obeys the Beer
’
s law within the 
concentration range of 5 to 25 µg/ml. 
2. PREFORMULATION  (COMPATABILITY) STUDIES: 
a) Infrared (IR) spectroscopic studies  
Infrared (IR) spectroscopic studies were carried out to confirm the 
compatibility between drug and the stabilizers used for the preparation of 
nanocrystals. The IR studies were performed for pure drug, stabilizers and physical 
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mixture of drug with stabilizers. The spectra studied at 4000cm
-1 
to 400 cm
-1 
were 
shown in (Table 2) and (Figure 11a-11m). The principal peaks for pure drug were 
observed at wave numbers 1373.36 cm
-1
, 1228.70 cm
-1
, 1186.26 cm
-1
, 1063.78 cm
-1
, 
815.92 cm
-1
, 753.23 cm
-1
, 701.15 cm
-1
. It was found from the spectra that there was 
no major shifting as well as any loss of functional peaks in the spectra of drug, 
stabilizers  and physical mixture of drug with stabilizers. This clearly indicated that 
there was no interaction between the drug and the polymer and the drug was present 
in its unchanged form. 
3. FORMULATION OF RAMIPRIL NANOCRYSTALS 
The ramipril nanocrystals were prepared by emulsion solvent diffusion 
method (Phanchaxari M Dandagi et al., 2011). The principle of this method  was  
based on the dissolution of the active drug substance in an organic solvent which was 
then added into a nonsolvent (miscible with the organic solvent). In the presence of, 
thereafter, the nanocrystals were precipitated. Basic advantage of the precipitation 
technique was that it was simple and had a low cost. Also, scale up was simple in this 
method (Phanchaxari M Dandagi et al., 2011). 
Ramipril nanocrystals were prepared by following process: 
a) Formulation of ramipril nanosuspensions; 
b) Lyophilization of nanosuspensions to obtain the nanocrystals. 
Various formulations of ramipril nanocrystals (F1 - F25) were prepared by 
using different stabilizers like HPMC K15M, PVP K30, β Cyclodextrin, SLS, and 
PEG 6000  at different concentrations (0.1%, 0.2%, 0.3%, 0.4%, 0.5%) were selected  
shown in (Table 3) 
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4. CHARACTERIZATION OF RAMIPRIL NANOCRYSTALS 
All the formulations were evaluated for its drug content, particle size, 
polydispersity index, and zeta potential,   in vitro drug release studies and solubility 
studies. 
a) Determination of drug content 
The drug content of all nanocrystal formulations (F1 to F25) was in the range 
of 88.00% to 96.00%. The results were shown in (Table 4). The results suggest that 
the process employed to prepare the nanocrystals shown uniform distribution of drug. 
b) In vitro dissolution studies 
The invitro dissolution studies of all formulations were compared with pure 
drug. The results of in vitro drug release studies from the ramipril nanocrystals were 
shown in the (Table 5a-5e) and in (Figure 12a-12e). when compared the In vitro 
release profile of all the formulations are significantly greater than that pure drug 
ramipril. 
Formulations (F1A – F1E) prepared using different concentration of stabilizer 
(HPMC K15M 0.1% to 0.5%) shown the percentage drug release of 53.39%, 61.10%, 
67.97%, 71.12%, and 74.81% at 120 mins respectively. 
Formulations (F2A – F2E) prepared using different concentration of stabilizer 
(PVP K30 0.1% to 0.5%) shown the percentage drug release of 73.29%, 74.04%, 
75.68%, 75.67%, and 78.78% at 120 mins respectively. 
Formulations (F3A – F3E) prepared using different concentration of stabilizer 
(β-cyclodextrin 0.1% to 0.5%) shown the percentage drug release of 75.69%, 77.98%, 
81.12%, 81.12%, and 83.43% at 120 mins respectively. 
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Formulations (F4A – F4E) prepared using different concentration of stabilizer 
(SLS 0.1% to 0.5%) shown the percentage drug release of 60.46%, 72.49%, 78.69%, 
81.02%, and 87.92% at 120 mins respectively. 
Formulations (F5A – F5E) prepared using different concentration of stabilizer 
( PEG 6000 0.1% to 0.5%) shown the percentage drug release of 57.18%, 61.06%, 
64.17%, 67.23%, and 71.76% at 120 mins respectively. 
The percentage drug release  of all the formulations were found to be in the 
following order 
0.1% ˂  0.2% ˂  0.3% ˂  0.4% ˂  0.5% 
The release rate of the drug from the nanocrystals were increased, on 
increasing the stabilizers concentration.  
The increased percentage drug release of stabilizer (HPMC K15M) having 
formulation (F1A to F1E) indicates that, stabilizer HPMC K15M was used for the 
suspension’s stabilization as this water soluble polymer offers adequate surface active 
properties and it indicates that they have increased the drug release (Amighi.K et al., 
2005). 
The increased percentage drug release of stabilizer (PVP K30) having 
formulation (F2A to F2E) indicates that, stabilizer PVP K30 was used as water 
soluble compound, in order to improve the drug dissolution rate (Noushin 
Bolourchian et al., 2013). 
The increased percentage drug release of stabilizer (β-cyclodextrin) having 
formulation (F3A to F3E) indicates that, stabilizer β-cyclodextrin to form a network 
through intermolecular interaction, that colud protect and it can self-associate in 
aqueous solution to form nano-scale aggregates that have a minimum hydrodynamic 
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radius in order to improve the drug dissolution rate (Phanchaxari M Dandagi et al., 
2011). 
The increased percentage drug release of stabilizer (SLS) having formulation 
(F4A to F4E) indicates that, SLS was used as dispersion stabilizer, it prevents 
agglomeration of precipitated nanocrystal in the formulation by increasing the 
activation energy and reduce the surface tension existing between the drug particle 
and the solvent by providing wettability to the particls, in order to improve the drug 
dissolution rate (Phanchaxari M Dandagi et al., 2011). 
The increased percentage drug release of stabilizer (PEG 6000) having 
formulation (F5A to F5E) indicates that, stabilizer PEG 6000 had long hydrophilic 
chain and it captured the water molecule through hydrogen bonding, which were 
formed between the hydroxyl group and ether bond of PEG and water molecule, in 
order to improve the drug dissolution rate (Peng Liu et al., 2011). 
c) Determination of Particle size and Zeta potential: 
i) Particle size: 
Particle size, size distribution and zeta potential were important 
characterizations of the nanocrystals because they govern  the other characterizations, 
such as saturation solubility and dissolution velocity, physical stability, or even 
biological performances (Dianrui Zhang et al., 2012). 
The average diameters and polydispersity index of  ramipril nanocrystals were 
listed in (Table 7) and (Figure 13a and13b). In the present study the particle size of 
ramipril nanocrystals were ranged between 80.3nm to 300.6 nm. 
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ii) Zeta potential 
The zeta potential of the nanocrystals were allowed predictions about the 
storage stability of colloidal dispersions. In general, the zeta potential value at least 
±30 mV can ensure the physically stable nanocrystals when using ionic surfactants for 
electric repulsion; however, a zeta potential about  ±20 mV can also signify long-term 
stability of the system when nonionic surfactants were applied for steric hindrance. In 
addition, the type of  a key variable that had prominent effect on the mean zeta 
potential value (Dianrui Zhang et al., 2012). 
The ramipril nanocrystals were characterized to evaluate the effect of 
stabilizers at different ratios and different  on surface charge of nanocrystals. The 
results were showed in (Table 8) and (Figure 14a and14b). 
Zeta potential values of the formulations code (F3C – F3E and F4D ‒  F4E) 
prepared with different showed negative zeta potential (-19.7mV to -24.7mV) which 
indicated a stable preparation. 
d) Solubility studies 
Solubility studies of pure drug (RAMIPRIL) and selected formulation (F3C to 
F3E and F4D to F4E) were shown in (Table 9) and (Figure 15a and 15b).  
Nanocrystal formulations (F3C to F3E and F4D to F4E) shown highest solubility in 
distilled water  as compared with pure drug. 
The solubility of formulations (F3C, F3D, F3E, F4D, F4E) and pure drug in 
phosphate buffer pH (6.8) were 1.177mg/10ml, 2.791mg/10ml, 5.680mg/10ml, 
2.294mg/10ml, 5.182mg/10ml and 0.547mg/10ml respectively. Thus the solubility of 
RAMIPRIL in nanocrystal formulations (F3E and F4E) was increased approximately  
by ten folds when compared to pure drug. 
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Hence, the noticeable increased saturation solubility of ramipril in the 
formulation of nanocrystals was mainly attributed to the decreased particle size and 
increased  surface area. The results can be explained by the Ostwald–Freundlich 
equation which demonstrates that the saturation  solubility of the drug  increases with 
reduction of particle size (Dianrui Zhang et al., 2012). 
5. SELECTION AND EVALUATION OF BEST FORMULATION: 
 From the above results characterization, the following two formulations were 
selected as the best formulation showing, 
For F3E 
  Particle size   :  80.3 nm. 
  In vitro drug release  :  85.74% in 2 hours 
  Solubility studies  :  3.565mg/10ml distilled water 
          5.68mg/10ml phosphate buffer pH(6.8) 
For F4E 
  Particle size   :  100.8 nm. 
  In vitro drug release  :  87.91% in 2 hours 
  Solubility studies  :  3.068mg/10ml distilled water 
          5.182mg/10ml phosphate buffer pH(6.8) 
a) Infrared (IR) spectroscopic studies: 
 Infrared (IR) spectroscopic studies were carried out for pure drug, stabilizers 
and selected nanocrystal formulations. The spectra studied at 4000cm
-1 
to 400 cm
-1 
were shown in (Table 2) and (Figure 11a-11m). It was found from the spectra that 
there was no major shifting as well as any loss of functional peaks in the spectra of 
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drug, stabilizers and selected formulations (F3E and F4E). This clearly indicated that 
there was no interaction between the drug and the polymer and the drug was present 
in its unchanged form. 
b) Morphological studies of nanocrystals by using Scanning Electron Microscopy 
(SEM): 
 The morphology of selected nanocrystal formulations (F3E and F$E) was 
examined by Scanning  Electron Microscopy (SEM).  The SEM image of formulation 
was shown in (Figure 16a and 16b).  It was observed that the particle size of 
Ramipril nanocrystal formulations (F3E and F4E) was relatively small, uniform, 
crystal in shape and the mean size of particles were lower than 1 µm. This data was 
agreement with obtained data from Malvern zeta sizer analysis (Rainer Muller .H et 
al., 2008). 
c) X-ray Powder Diffraction (XRPD) analysis: 
 The  XRPD patterns of pure drug  ( Ramipril)  and formulations (F3E, F4E) 
were presented in (Figure 17a, 17b and 17c). 
 The  XRPD patterns of pure drug showed numerous sharp peaks (at 2θ 15.00°, 
16.80°, 20.90°, 23.00°, 25.40° and 34.31°) which are the characteristic of a crystalline 
compound. Drug crystallinity peaks were also detectable in formulation as shown in 
(Figure 17b and 17c). 
This result confirmed that the characteristic peaks were still preserved 
indicating the crystalline state was not changed. 
As we know, the amorphous form can generally enhance the dissolution rate 
and bioavailability of drugs due to its high-energy.  According to that principle and 
with the XRPD analysis considered, the enhancement of dissolution rate of Ramipril 
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may be due to the reduction of particle size or the influence of stabilizers rather than 
the appearance of amorphous form.  Moreover, compared with the amorphous form, 
the maintenance of crystalline state was beneficial to a long-term stability (Dianrui 
Zhang et al., 2012). 
 
 
 
 
TABLE 1: CALIBRATION OF RAMIPRIL USING PHOPSPHATE BUFFER 
pH (6.8) 
 
S. NO CONCENTRATION(μg/ml) ABSORBANCE ± SD* 
1 05 0.023 ± 0.0035 
2 10 0.042 ± 0.0025 
3 15 0.065 ± 0.0060 
4 20 0.083 ± 0.0083 
5 25 0.102 ± 0.0090 
  
      n=3*                                                                                                    γ = 0.99958 
 
 
 
 
 
 
 
 
 
TABLE 2: IR PEAKS OF DRUG, STABILIZERS, PHYSICAL MIXTURE OF 
DRUG WITH STABILIZERS AND FORMULATIONS 
 
S. 
NO 
DESCRIPTION 
CHARACTERISTIC PEAKS (cm
-1
) 
OBTAINED 
1 RAMIPRIL 
 
1373.36, 1228.70, 1063.78, 815.92, 753.23, 701.15 
2 HPMC K15M 
 
3642.69, 2934.79, 1650.16, 1459.20, 945.15 
3 
 
PVP K30 
 
3748.78, 3398.69, 2956.01, 1667.52,1502.60 
4 
 
β-
CYCLODEXTRIN 
 
1490.06, 1457.27, 1363.72, 948.04, 651.00, 431.10 
5 
 
SLS 
 
1654.01, 1470.77, 1248.95, 834.24, 634.60, 591.20 
6 
 
PEG 6000 
 
2165.17, 1650.16, 1469.81, 1240.27, 961.55 
7 
RAMIPRIL + 
HPMC K15M 
2935.76, 1743.71, 1187.23, 755.16, 355.88 
8 
RAMIPRIL + PVP 
K30 
2867.28, 1654.01, 1442.80, 1187.23, 701.15 
9 RAMIPRIL+ β-CD 2932.86, 1653.05, 1157.33, 1029.06, 702.11 
10 RAMIPRIL+ SLS 2920.32, 1743.71, 1654.01, 1465.95, 1081.44 
11 
RAMIPRIL + PEG 
6000 
3281.02, 1349.25, 1280.78,845.81, 751.30 
12 
FORMULATION 
(F3E) 
2932.86, 1653.05, 1157.33, 1029.06, 702.11 
13 
FORMULATION 
(F4E) 
2920.32, 1743.71, 1654.01, 1465.95, 1081.44 
TABLE 3:  COMPOSITION OF RAMIPRIL NANOCRYSTALS 
S.NO 
 
FORMULATION  
CODE 
SOLVENT/ORGANIC 
PHASE 
DRUG 
CONCENTRATION(mg/10ml) 
STABILIZERS 
CONCENTRATION(%) 
1 F1A METHANOL 100mg in 10ml HPMC K15M(0.1%) 
2 F1B METHANOL 100mg in 10ml HPMC K15M(0.2%) 
3 F1C METHANOL 100mg in 10ml HPMC K15M(0.3%) 
4 F1D METHANOL 100mg in 10ml HPMC K15M(0.4%) 
5 F1E METHANOL 100mg in 10ml HPMC K15M(0.5%) 
6 F2A METHANOL 100mg in 10ml PVP K30(0.1%) 
7 F2B METHANOL 100mg in 10ml PVP K30(0.2%) 
8 F2C METHANOL 100mg in 10ml PVP K30(0.3%) 
9 F2D METHANOL 100mg in 10ml PVP K30(0.4%) 
10 F2E METHANOL 100mg in 10ml PVP K30(0.5%) 
11 F3A METHANOL 100mg in 10ml BCD(0.1%) 
12 F3B METHANOL 100mg in 10ml BCD(0.2%) 
13 F3C METHANOL 100mg in 10ml BCD(0.3%) 
14 F3D METHANOL 100mg in 10ml BCD(0.4%) 
15 F3E METHANOL 100mg in 10ml BCD(0.5%) 
16 F4A METHANOL 100mg in 10ml SLS(0.1%) 
17 F4B METHANOL 100mg in 10ml SLS(0.2%) 
18 F4C METHANOL 100mg in 10ml SLS(0.3%) 
19 F4D METHANOL 100mg in 10ml SLS(0.4%) 
20 F4E METHANOL 100mg in 10ml SLS(0.5%) 
21 F5A METHANOL 100mg in 10ml PEG6000(0.1%) 
22 F5B METHANOL 100mg in 10ml PEG6000(0.2%) 
23 F5C METHANOL 100mg in 10ml PEG6000(0.3%) 
24 F5D METHANOL 100mg in 10ml PEG6000(0.4%) 
25 F5E METHANOL 100mg in 10ml PEG6000(0.5%) 
 
         TABLE 4: DRUG CONTENT OF RAMIPRIL NANOCRYSTALS 
S.No 
STABILIZERS 
CONCENTRATION 
FORMULATION 
CODE 
AVG±SD 
1 HPMC K15M(0.1%) F1A 93.63±1.6226 
2 HPMC K15M(0.2%) FIB 89.63±1.9561 
3 HPMC K15M(0.3%) F1C 89.70±1.3856 
4 HPMC K15M(0.4%) F1D 88.00±0.0000 
5 HPMC K15M(0.5%) F1E 89.50±2.0621 
6 PVP K30(0.1%) F2A 92.86±1.8013 
7 PVP K30(0.2%) F2B 92.00±1.6055 
8 PVP K30(0.3%) F2C 90.33±1.0237 
9 PVP K30(0.4%) F2D 93.66±1.1547 
10 PVP K30(0.5%) F2E 93.00±1.4641 
11 BCD(0.1%) F3A 95.86±0.5011 
12 BCD(0.2%) F3B 95.33±1.5166 
13 BCD(0.3%) F3C 91.66±1.1547 
14 BCD(0.4%) F3D 95.33±1.5166 
15 BCD(0.5%) F3E 93.00±1.0000 
16 SLS(0.1%) F4A 90.66±1.5166 
17 SLS(0.2%) F4B 91.66±1.1547 
18 SLS(0.3%) F4C 94.33±1.1547 
19 SLS(0.4%) F4D 92.33±1.1547 
20 SLS(0.5%) F4E 96.00±1.7320 
21 PEG6000(0.1%) F5A 93.66±1.1547 
22 PEG6000(0.2%) F5B 95.33±0.5166 
23 PEG6000(0.3%) F5C 96.00±1.7320 
24 PEG6000(0.4%) F5D 95.33±1.5166 
25 PEG6000(0.5%) F5E 96.00±1.7320 
 
n=3*
TABLE 5a: IN VITRO RELEASE PROFILE OF RAMIPRIL NANOCRYSTALS  CONTAINING HPMC K15M AS STABILIZER 
TIME 
IN 
Mins 
FORMULATION CODE 
PURE DRUG±SD 
F1A±SD F1B±SD F1C±SD F1D±SD F1E±SD 
5 12.85±1.23 21.05±1.29 24.04±1.23 30.00±1.29 27.02±1.29 9.87±1.29 
10 18.89±1.42 27.14±1.29 30.88±1.24 36.88±1.29 33.88±1.29 15.89±1.29 
20 25.70±1.44 32.51±1.30 37.02±1.60 43.05±1.29 40.03±2.24 22.69±1.30 
30 31.16±1.49 38.07±1.32 42.65±1.64 48.77±1.31 47.21±1.32 28.10±1.32 
40 37.03±1.36 43.87±1.30 49.90±1.45 54.47±1.30 53.68±2.24 34.00±1.30 
60 43.20±2.64 50.82±1.31 56.14±1.53 59.99±1.29 60.68±1.25 40.90±1.31 
90 47.91±0.66 55.58±1.32 61.66±1.49 66.28±1.31 67.73±2.26 45.60±1.32 
120 53.39±1.51 61.10±2.26 67.97±2.33 71.12±1.32 74.81±2.28 50.32±1.33 
 
n=3* 
TABLE 5b: IN VITRO RELEASE PROFILE OF RAMIPRIL NANOCRYSTALS  CONTAINING PVP K30 AS STABILIZER 
n=3* 
 
TIME 
IN 
Mins 
FORMULATION CODE 
PURE DRUG±SD 
F2A±SD F2B±SD F2C±SD F2D±SD F2E±SD 
5 28.51±2.23 25.53±1.29 32.24±1.29 34.48±1.29 36.71±1.29 9.87±1.29 
10 33.14±2.24 32.38±1.29 38.38±1.29 39.14±1.29 42.88±1.29 15.89±1.29 
20 40.04±2.26 39.27±1.30 45.31±1.30 43.83±1.30 48.34±1.30 22.69±1.30 
30 45.71±2.29 45.69±2.27 51.06±1.32 49.56±1.32 54.14±1.32 28.10±1.32 
40 52.19±1.32 53.65±2.25 57.49±1.30 56.75±1.30 59.79±1.30 34.00±1.30 
60 59.19±1.33 60.66±2.26 63.02±2.24 62.28±1.28 66.08±1.30 40.90±1.31 
90 66.22±1.33 66.96±2.61 69.33±1.32 68.59±1.31 73.16±1.31 45.60±1.32 
120 73.29±1.34 74.04±2.62 75.68±1.31 75.67±1.32 78.78±1.32 50.32±1.33 
TABLE 5c: IN VITRO RELEASE PROFILE OF RAMIPRIL NANOCRYSTALS  CONTAINING β-CYCLODEXTRIN AS 
STABILIZER 
 
n=3* 
TIME 
IN 
Mins 
FORMULATION CODE 
PURE DRUG±SD 
F3A±SD F3B±SD F3C±SD F3D±SD F3E±SD 
5 32.24±1.29 34.48±1.29 38.20±1.29 40.44±1.29 42.68±1.29 9.87±1.29 
10 38.38±1.29 41.38±1.29 45.13±1.29 47.38±1.29 49.63±1.29 15.89±1.29 
20 45.31±1.30 47.57±1.29 52.09±1.30 54.35±1.30 56.61±1.30 22.69±1.30 
30 51.06±1.32 53.36±1.31 57.94±1.32 60.24±1.32 62.53±1.32 28.10±1.32 
40 58.23±2.24 59.02±1.30 64.31±1.30 66.58±1.30 68.85±1.30 34.00±1.30 
60 63.77±1.32 63.82±1.31 70.62±1.31 72.91±1.31 75.20±1.31 40.90±1.31 
90 70.09±2.26 70.88±1.32 75.49±1.32 77.78±1.32 80.08±1.32 45.60±1.32 
120 75.69±1.33 77.98±1.32 81.12±1.31 83.43±1.31 85.74±1.31 50.32±1.33 
TABLE 5d: IN VITRO RELEASE PROFILE OF RAMIPRIL NANOCRYSTALS  CONTAINING SLS AS STABILIZER 
 
TIME 
IN 
Mins 
FORMULATION CODE 
PURE DRUG±SD 
F4A±SD F4B±SD F4C±SD F4D±SD F4E±SD 
5 28.51±2.23 24.04±2.23 32.24±1.29 35.22±2.23 39.69±2.23 9.87±1.29 
10 32.40±1.30 30.88±2.24 39.13±1.29 42.13±2.24 46.63±2.24 15.89±1.29 
20 36.30±1.29 37.76±2.26 46.06±1.30 49.07±2.26 53.60±2.26 22.69±1.30 
30 40.42±2.61 43.40±2.29 51.82±1.32 54.88±2.29 59.47±2.29 28.10±1.32 
40 46.20±2.43 51.39±2.27 58.24±0.02 60.53±2.27 66.57±1.32 34.00±1.30 
60 50.93±2.45 58.39±2.28 64.53±1.28 66.83±2.42 73.64±1.33 40.90±1.31 
90 55.68±1.47 65.42±2.29 71.59±1.28 73.90±1.64 80.76±1.33 45.60±1.32 
120 60.46±2.49 72.49±2.31 78.69±1.29 81.02±1.65 87.91±1.34 50.32±1.33 
 
n=3* 
 
TABLE 5e: IN VITRO RELEASE PROFILE OF RAMIPRIL NANOCRYSTALS  CONTAINING PEG 6000 AS STABILIZER 
 
TIME 
IN 
Mins 
FORMULATION CODE 
PURE DRUG±SD 
F5A±SD F5B±SD F5C±SD F5D±SD F5E±SD 
5 15.09±2.23 19.56±2.23 22.54±1.29 24.78±1.29 27.02±1.29 9.87±1.29 
10 21.88±2.24 26.38±2.24 28.63±2.24 31.63±1.29 33.13±2.24 15.89±1.29 
20 26.48±2.26 31.75±1.31 35.50±2.25 37.77±2.24 37.79±2.25 22.69±1.30 
30 31.95±2.29 37.30±1.33 41.11±2.28 43.41±2.28 43.43±2.28 28.10±1.32 
40 37.81±2.27 43.11±1.32 46.89±2.26 49.16±2.26 50.68±2.44 34.00±1.30 
60 44.73±2.28 48.56±1.61 53.85±2.28 55.40±1.61 57.67±1.46 40.90±1.31 
90 50.94±1.47 54.05±2.28 59.37±1.34 61.67±1.46 64.69±1.48 45.60±1.32 
120 57.18±1.65 61.06±2.29 64.17±1.34 67.23±1.65 71.76±1.50 50.32±1.33 
 
n=3*
TABLE 6a: EFFECT OF PARTICLE SIZE ON IN VITRO RELEASE STUDIES 
OF RAMIPRIL NANOCRYSTALS CONTAINING β-CYCLODEXTRIN AND 
SLS AS STABILIZER 
 
FORMULATION    
CODE 
STABILIZERS 
CONCENTRATION MEAN DIAMETER(nm) 
% DRUG 
RELEASE 
F3C BCD(0.3%) 300.6 81.12 
F3D BCD(0.4%) 110.6 83.43 
F3E BCD(0.5%) 80.3 85.74 
F4D SLS(0.4%) 109.3 81.02 
F4E SLS(0.5%) 100.8 87.91 
 
TABLE 7: EFFECT OF PARTICLE SIZE OF RAMIPRIL NANOCRYSTALS 
CONTAINING β-CYCLODEXTRIN AND SLS AS STABILIZER 
 
FORMULATION 
CODE 
STABILIZERS 
CONCENTRATION 
MEAN 
DIAMETER(nm) PDI 
F3C BCD(0.3%) 300.6 0.324 
F3D BCD(0.4%) 110.6 0.416 
F3E BCD(0.5%) 80.3 0.232 
F4D SLS(0.4%) 109.3 0.457 
F4E SLS(0.5%) 100.8 0.416 
 
TABLE 8: ZETA POTENTIAL VALUES OF RAMIPRIL NANOCRYSTALS 
FORMULATION 
CODE 
STABILIZERS 
CONCENTRATION 
ZETA 
POTENTIAL(mV) 
F3C BCD(0.3%) -20.5 
F3D BCD(0.4%) -22.3 
F3E BCD(0.5%) -19.7 
F4D SLS(0.4%) -24.7 
F4E SLS(0.5%) -21.4 
 
 
TABLE 9: COMPARISON OF SOLUBILITY OF SELECTED 
FORMULATION WITH PURE DRUG 
S. 
NO 
SOLVENT 
USED 
SOLUBILITY IN EACH SOLVENT(mg/10ml) 
PURE 
DRUG 
F3C F3D F3E F4D F4E 
1 
DISTILLED 
WATER 
0.174±0.02 0.879±0.05 2.238±0.09 3.565±0.09 1.077±0.05 3.068±0.09 
2 
PHOSPHATE 
BUFFER 
Ph(6.8) 
0.547±0.05 1.177±0.05 2.791±0.09 5.68±0.14 2.294±0.09 5.182±0.14 
 
n=3* 
  
FIGURE 10a:  λ MAX OF RAMIPRIL USING PHOSPHATE BUFFER 
pH (6.8) 
 
 
 
 
FIGURE 10b: CALIBRATION OF RAMIPRIL USING PHOSPHATE 
BUFFER pH (6.8) 
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 FIGURE 11a: IR SPECTRUM OF  RAMIPRIL 
 
 
FIGURE 11b: IR SPECTRUM OF β-CYCLO DEXTRIN 
 
 FIGURE 11c: IR SPECTRUM OF HPMC K15M 
 
 
FIGURE 11d: IR SPECTRUM OF PEG 6000 
 
 FIGURE 11e: IR SPECTRUM OF PVP K30 
 
 
 
FIGURE 11f: IR SPECTRUM OF SLS 
 FIGURE 11g: IR SPECTRUM OF RAMIPRIL + HPMC K15M 
 
 
 
FIGURE 11h: IR SPECTRUM OF RAMIPRIL + PVP K30 
 
 
 FIGURE 11i: IR SPECTRUM OF RAMIPRIL + β-CYCLO DEXTRIN 
 
 
 
 
FIGURE 11j: IR SPECTRUM OF RAMIPRIL + SLS 
 
 
  
FIGURE 11k: IR SPECTRUM OF RAMIPRIL + PEG 6000 
 
 
 
FIGURE 11l: IR SPECTRUM OF F3E 
 
 
  
 
FIGURE 11m: IR SPECTRUM OF F4E 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 12a: COMPARISON OF IN VITRO DISSOLUTION 
RELEASE PROFILE OF RAMIPRIL  NANOCRYSTALS 
CONTAINING HPMC K15M AS STABILIZER 
 
FIGURE 12b: COMPARISON OF IN VITRO DISSOLUTION 
RELEASE PROFILE OF RAMIPRIL  NANOCRYSTALS 
CONTAINING PVP K30 AS STABILIZER 
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 FIGURE 12c: COMPARISON OF IN VITRO DISSOLUTION 
RELEASE PROFILE OF RAMIPRIL  NANOCRYSTALS 
CONTAINING β-CYCLO DEXTRIN AS STABILIZER 
 
FIGURE 12d: COMPARISON OF IN VITRO DISSOLUTION 
RELEASE PROFILE OF RAMIPRIL  NANOCRYSTALS 
CONTAINING SLS AS STABILIZER 
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 FIGURE 12e: COMPARISON OF IN VITRO DISSOLUTION 
RELEASE PROFILE OF RAMIPRIL  NANOCRYSTALS 
CONTAINING PEG 6000 AS STABILIZER 
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FIGURE 13a: PARTICLE SIZE DISTRIBUTION CURVE OF 
FORMULATIONS  F3C, F3D AND F3E 
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FIGURE 13b: PARTICLE SIZE DISTRIBUTION CURVE OF 
FORMULATIONS F4D AND F4E 
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FIGURE14a: ZETA POTENTIAL CURVE OF FORMULATIONS F3C, 
F3D, AND F3E 
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FIGURE14b: ZETA POTENTIAL CURVE OF FORMULATIONS F4D, 
AND F4E 
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FIGURE 15a: COMPARISON OF SOLUBILITY OF SELECTED 
FORMULATIONS (F3C, F3D, F3E, F4D AND F4E) WITH PURE DRUG 
 
 
 
FIGURE 15b: COMPARISON OF SOLUBILITY OF SELECTED 
FORMULATIONS (F3C, F3D, F3E, F4D AND F4E) WITH PURE DRUG 
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FIGURE 16a: SCANNING ELECTRON MICROSCOPY (SEM) IMAGE OF 
BEST FORMULATION (F3E) 
 
 
 
  
 
FIGURE 16b: SCANNING ELECTRON MICROSCOPY (SEM) IMAGE OF 
BEST FORMULATION (F4E) 
  
 
FIGURE 17a: X RAY DIFFRACTION PATTERN OF RAMIPRIL 
PURE DRUG 
 
 
  
 
FIGURE 17b: X RAY DIFFRACTION PATTERN OF BEST 
FORMULATION (F3E) 
 
 
 
 
 
 
FIGURE 17c: X RAY DIFFRACTION PATTERN OF BEST 
FORMULATION (F4E) 
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CHAPTER - XI 
SUMMARY AND CONCLUSION 
 In the present study an attempt has been made to develop nanocrystals of 
Ramipril in order to enhance solubility and dissolution rate by decreasing 
particle size of drug. 
 The results of compatibility studies by Infrared spectroscopy showed no 
interaction between the drug and stabilizers. 
 The Ramipril nanocrystals were successfully prepared by emulsion solvent 
diffusion method using different concentrations of stabilizers (HPMC K15M, 
PVP K30, β-CYCLODEXTRIN, SODIUM LAURYL SULPHATE, and PEG 
6000). 
 The presence of stabilizers made the nanocrystal formulations more stable 
with increasing drug release.  
 Particle size analyzer used to explore the particle size of Ramipril nanocrystals 
showed a suitable particle size in the range of 80.3nm to 300.6 nm. 
 The polydispersity index of selected nanocrystal formulations(F3C, F3D, F3E, 
F4D, and F4E) was less than 0.5, which indicated a narrow size  distribution 
of particles. 
 Zeta potential value of Ramipril nanocrystals showed a negative surface 
charge (-19.7mV to -24.7mV). In vitro release study of all the formulations 
were showed a increased drug release with increase in concentration of 
different stabilizers (HPMC K15M, PVP K30, β-CYCLODEXTRIN, 
SODIUM LAURYL SULPHATE, and PEG 6000). Dissolution rate of all the 
formulations were improved when compared to pure drug. 
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 On the basis of drug release data F3C, F3D, F3E, F4D, and F4E showed a 
good release profile with more than 80% in 2 hours. 
 The solubility of selected formulations (F3C, F3D, F3E, F4D, and F4E) in 
phosphate buffer pH(6.8) increased ten folds when compared to pure drug. 
 SEM studies confirmed the morphology of the nanocrystal formulations. The 
crystalline state of the nanocrystal formulation was not altered according to 
the XRPD analysis. 
 
CONCLUSION: 
 Hence, it was concluded that nanocrystallization was a good approach to 
enhance the dissolution property of Ramipril by emulsion solvent diffusion method. 
The solubility and in vitro dissolution studies suggested that the nanocrystal 
formulations can improve the bioavailability of the Ramipril by improving its 
solubility and dissolution rate when compared to pure drug. Thus nanocrystal drug 
delivery system can adopted to increase the solubility and dissolution rate of poorly 
soluble drug like Ramipril to enhance their bioavailability. 
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